1
|
Cappello G, Romano V, Neri E, Fournier L, D'Anastasi M, Laghi A, Zamboni GA, Beets-Tan RGH, Schlemmer HP, Regge D. A European Society of Oncologic Imaging (ESOI) survey on the radiological assessment of response to oncologic treatments in clinical practice. Insights Imaging 2023; 14:220. [PMID: 38117394 PMCID: PMC10733253 DOI: 10.1186/s13244-023-01568-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2023] [Accepted: 11/08/2023] [Indexed: 12/21/2023] Open
Abstract
OBJECTIVES To present the results of a survey on the assessment of treatment response with imaging in oncologic patient, in routine clinical practice. The survey was promoted by the European Society of Oncologic Imaging to gather information for the development of reporting models and recommendations. METHODS The survey was launched on the European Society of Oncologic Imaging website and was available for 3 weeks. It consisted of 5 sections, including 24 questions related to the following topics: demographic and professional information, methods for lesion measurement, how to deal with diminutive lesions, how to report baseline and follow-up examinations, which previous studies should be used for comparison, and role of RECIST 1.1 criteria in the daily clinical practice. RESULTS A total of 286 responses were received. Most responders followed the RECIST 1.1 recommendations for the measurement of target lesions and lymph nodes and for the assessment of tumor response. To assess response, 48.6% used previous and/or best response study in addition to baseline, 25.2% included the evaluation of all main time points, and 35% used as the reference only the previous study. A considerable number of responders used RECIST 1.1 criteria in daily clinical practice (41.6%) or thought that they should be always applied (60.8%). CONCLUSION Since standardized criteria are mainly a prerogative of clinical trials, in daily routine, reporting strategies are left to radiologists and oncologists, which may issue local and diversified recommendations. The survey emphasizes the need for more generally applicable rules for response assessment in clinical practice. CRITICAL RELEVANCE STATEMENT Compared to clinical trials which use specific criteria to evaluate response to oncological treatments, the free narrative report usually adopted in daily clinical practice may lack clarity and useful information, and therefore, more structured approaches are needed. KEY POINTS · Most radiologists consider standardized reporting strategies essential for an objective assessment of tumor response in clinical practice. · Radiologists increasingly rely on RECIST 1.1 in their daily clinical practice. · Treatment response evaluation should require a complete analysis of all imaging time points and not only of the last.
Collapse
Affiliation(s)
- Giovanni Cappello
- Radiology Unit, Candiolo Cancer Institute, FPO-IRCCS, Str. Prov.le 142 km 3.95, 10060, Candiolo (Turin), Italy.
| | - Vittorio Romano
- Radiology Unit, Candiolo Cancer Institute, FPO-IRCCS, Str. Prov.le 142 km 3.95, 10060, Candiolo (Turin), Italy
- Department of Surgical Sciences, University of Turin, Turin, Italy
| | - Emanuele Neri
- Department of Translational Research, Academic Radiology, University of Pisa, 56124, Pisa, Italy
| | - Laure Fournier
- Radiology Department, Hôpital Européen Georges Pompidou, AP-HP, Université de Paris, 20 Rue Leblanc, 75015, Paris, France
| | - Melvin D'Anastasi
- Medical Imaging Department, Mater Dei Hospital, University of Malta, Msida, 2090, MSD, Malta
| | - Andrea Laghi
- Department of Medical Surgical Sciences and Translational Medicine, Sapienza University of Rome, Sant'Andrea University Hospital, Via Di Grottarossa, 1035-1039, 00189, Rome, Italy
| | - Giulia A Zamboni
- Department of Diagnostics and Public Health, Institute of Radiology, University of Verona, Policlinico GB Rossi, P.Le LA Scuro 10, 37134, Verona, Italy
| | - Regina G H Beets-Tan
- Department of Radiology, The Netherlands Cancer Institute, P.O. Box 90203, 1006 BE, Amsterdam, The Netherlands
- GROW School for Oncology and Developmental Biology, University of Maastricht, Maastricht, The Netherlands
| | - Heinz-Peter Schlemmer
- Department of Radiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120, Heidelberg, Germany
| | - Daniele Regge
- Radiology Unit, Candiolo Cancer Institute, FPO-IRCCS, Str. Prov.le 142 km 3.95, 10060, Candiolo (Turin), Italy
- Academic Radiology, Department of Translational Research on New Technologies in Medicine and Surgery, University of Pisa, Via Roma 67, Pisa, 56126, Italy
| |
Collapse
|
2
|
Habert P, Decoux A, Chermati L, Gibault L, Thomas P, Varoquaux A, Le Pimpec-Barthes F, Arnoux A, Juquel L, Chaumoitre K, Garcia S, Gaubert JY, Duron L, Fournier L. Best imaging signs identified by radiomics could outperform the model: application to differentiating lung carcinoid tumors from atypical hamartomas. Insights Imaging 2023; 14:148. [PMID: 37726504 PMCID: PMC10509085 DOI: 10.1186/s13244-023-01484-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2023] [Accepted: 07/17/2023] [Indexed: 09/21/2023] Open
Abstract
OBJECTIVES Lung carcinoids and atypical hamartomas may be difficult to differentiate but require different treatment. The aim was to differentiate these tumors using contrast-enhanced CT semantic and radiomics criteria. METHODS Between November 2009 and June 2020, consecutives patient operated for hamartomas or carcinoids with contrast-enhanced chest-CT were retrospectively reviewed. Semantic criteria were recorded and radiomics features were extracted from 3D segmentations using Pyradiomics. Reproducible and non-redundant radiomics features were used to training a random forest algorithm with cross-validation. A validation-set from another institution was used to evaluate of the radiomics signature, the 3D 'median' attenuation feature (3D-median) alone and the mean value from 2D-ROIs. RESULTS Seventy-three patients (median 58 years [43‒70]) were analyzed (16 hamartomas; 57 carcinoids). The radiomics signature predicted hamartomas vs carcinoids on the external dataset (22 hamartomas; 32 carcinoids) with an AUC = 0.76. The 3D-median was the most important in the model. Density thresholds < 10 HU to predict hamartoma and > 60 HU to predict carcinoids were chosen for their high specificity > 0.90. On the external dataset, sensitivity and specificity of the 3D-median and 2D-ROIs were, respectively, 0.23, 1.00 and 0.13, 1.00 < 10 HU; 0.63, 0.95 and 0.69, 0.91 > 60 HU. The 3D-median was more reproducible than 2D-ROIs (ICC = 0.97 95% CI [0.95‒0.99]; bias: 3 ± 7 HU limits of agreement (LoA) [- 10‒16] vs. ICC = 0.90 95% CI [0.85‒0.94]; bias: - 0.7 ± 21 HU LoA [- 4‒40], respectively). CONCLUSIONS A radiomics signature can distinguish hamartomas from carcinoids with an AUC = 0.76. Median density < 10 HU and > 60 HU on 3D or 2D-ROIs may be useful in clinical practice to diagnose these tumors with confidence, but 3D is more reproducible. CRITICAL RELEVANCE STATEMENT Radiomic features help to identify the most discriminating imaging signs using random forest. 'Median' attenuation value (Hounsfield units), extracted from 3D-segmentations on contrast-enhanced chest-CTs, could distinguish carcinoids from atypical hamartomas (AUC = 0.85), was reproducible (ICC = 0.97), and generalized to an external dataset. KEY POINTS • 3D-'Median' was the best feature to differentiate carcinoids from atypical hamartomas (AUC = 0.85). • 3D-'Median' feature is reproducible (ICC = 0.97) and was generalized to an external dataset. • Radiomics signature from 3D-segmentations differentiated carcinoids from atypical hamartomas with an AUC = 0.76. • 2D-ROI value reached similar performance to 3D-'median' but was less reproducible (ICC = 0.90).
Collapse
Affiliation(s)
- Paul Habert
- Imaging Department, Hopital Nord, APHM, Aix Marseille University, Marseille, France.
- LIIE, Aix Marseille Univ, Marseille, France.
- PARCC UMRS 970, INSERM, Université Paris Cité, Paris, France.
| | - Antoine Decoux
- PARCC UMRS 970, INSERM, Université Paris Cité, Paris, France
| | - Lilia Chermati
- Imaging Department, Hopital Nord, APHM, Aix Marseille University, Marseille, France
| | - Laure Gibault
- Department of Pathology, Hôpital Européen Georges Pompidou, Assistance, Publique Hôpitaux de Paris, Paris, France
| | - Pascal Thomas
- Service de Chirurgie Thoracique et Transplantation Pulmonaire, Hôpital Nord, Chemin des Bourrely, Aix Marseille Université, 13015, Marseille, France
| | - Arthur Varoquaux
- Department of Radiology, La Conception Hospital, Assistance Publique-Hôpitaux de Marseille, Aix-Marseille University, 13005, Marseille, France
| | | | - Armelle Arnoux
- AP-HP, Hopital Européen Georges Pompidou, Unité de Recherche Clinique, Centre d'Investigation Clinique 1418 Épidémiologie Clinique, INSERM, Université Paris Cité, Paris, France
| | - Loïc Juquel
- Service d'anatomie et Cytologie Pathologiques, Hôpital Nord, Chemin Des Bourrely, 13015, Marseille, France
- U1068-CRCM, Aix Marseille Université, 13015, Marseille, France
| | - Kathia Chaumoitre
- Imaging Department, Hopital Nord, APHM, Aix Marseille University, Marseille, France
| | - Stéphane Garcia
- Service d'anatomie et Cytologie Pathologiques, Hôpital Nord, Chemin Des Bourrely, 13015, Marseille, France
- U1068-CRCM, Aix Marseille Université, 13015, Marseille, France
| | - Jean-Yves Gaubert
- LIIE, Aix Marseille Univ, Marseille, France
- Department of Radiology, AP-HM, Hôpital La Timone, 13005, Marseille, France
| | - Loïc Duron
- PARCC UMRS 970, INSERM, Université Paris Cité, Paris, France
- Department of Neuroradiology, Alphonse de Rothschild Foundation Hospital, 75019, Paris, France
| | - Laure Fournier
- AP-HP, Hopital Européen Georges Pompidou, PARCC UMRS 970, INSERM, Université Paris Cité, Paris, France
| |
Collapse
|
3
|
Decoux A, Duron L, Habert P, Roblot V, Arsovic E, Chassagnon G, Arnoux A, Fournier L. Comparative performances of machine learning algorithms in radiomics and impacting factors. Sci Rep 2023; 13:14069. [PMID: 37640728 PMCID: PMC10462640 DOI: 10.1038/s41598-023-39738-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2023] [Accepted: 07/30/2023] [Indexed: 08/31/2023] Open
Abstract
There are no current recommendations on which machine learning (ML) algorithms should be used in radiomics. The objective was to compare performances of ML algorithms in radiomics when applied to different clinical questions to determine whether some strategies could give the best and most stable performances regardless of datasets. This study compares the performances of nine feature selection algorithms combined with fourteen binary classification algorithms on ten datasets. These datasets included radiomics features and clinical diagnosis for binary clinical classifications including COVID-19 pneumonia or sarcopenia on CT, head and neck, orbital or uterine lesions on MRI. For each dataset, a train-test split was created. Each of the 126 (9 × 14) combinations of feature selection algorithms and classification algorithms was trained and tuned using a ten-fold cross validation, then AUC was computed. This procedure was repeated three times per dataset. Best overall performances were obtained with JMI and JMIM as feature selection algorithms and random forest and linear regression models as classification algorithms. The choice of the classification algorithm was the factor explaining most of the performance variation (10% of total variance). The choice of the feature selection algorithm explained only 2% of variation, while the train-test split explained 9%.
Collapse
Affiliation(s)
- Antoine Decoux
- Université Paris Cité, PARCC UMRS 970, INSERM, Paris, France
- Unité de Recherche Clinique, Center d'Investigation Clinique 1418 Épidémiologie Clinique, Université Paris Cité, AP-HP, Hôpital Européen Georges Pompidou, INSERM, Paris, France
| | - Loic Duron
- Université Paris Cité, PARCC UMRS 970, INSERM, Paris, France
- Department of Radiology, Hôpital Fondation Ophtalmologique Adolphe de Rothschild, Paris, France
| | - Paul Habert
- Université Paris Cité, PARCC UMRS 970, INSERM, Paris, France
- Imaging Department, Hôpital Nord, APHM, Aix Marseille University, Marseille, France
- Aix Marseille Univ, LIIE, Marseille, France
| | - Victoire Roblot
- Université Paris Cité, PARCC UMRS 970, INSERM, Paris, France
| | - Emina Arsovic
- Université Paris Cité, PARCC UMRS 970, INSERM, Paris, France
| | - Guillaume Chassagnon
- Department of Radiology, Université Paris Cité, AP-HP, Hôpital Cochin, Paris, France
| | - Armelle Arnoux
- Unité de Recherche Clinique, Center d'Investigation Clinique 1418 Épidémiologie Clinique, Université Paris Cité, AP-HP, Hôpital Européen Georges Pompidou, INSERM, Paris, France
| | - Laure Fournier
- Department of Radiology, Université Paris Cité, AP-HP, Hôpital Européen Georges Pompidou, PARCC UMRS 970, INSERM, Paris, France.
| |
Collapse
|
4
|
Pasquier D, Bidaut L, Oprea-Lager DE, deSouza NM, Krug D, Collette L, Kunz W, Belkacemi Y, Bau MG, Caramella C, De Geus-Oei LF, De Caluwé A, Deroose C, Gheysens O, Herrmann K, Kindts I, Kontos M, Kümmel S, Linderholm B, Lopci E, Meattini I, Smeets A, Kaidar-Person O, Poortmans P, Tsoutsou P, Hajjaji N, Russell N, Senkus E, Talbot JN, Umutlu L, Vandecaveye V, Verhoeff JJC, van Oordt WMVDH, Zacho HD, Cardoso F, Fournier L, Van Duijnhoven F, Lecouvet FE. Designing clinical trials based on modern imaging and metastasis-directed treatments in patients with oligometastatic breast cancer: a consensus recommendation from the EORTC Imaging and Breast Cancer Groups. Lancet Oncol 2023; 24:e331-e343. [PMID: 37541279 DOI: 10.1016/s1470-2045(23)00286-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2023] [Revised: 06/06/2023] [Accepted: 06/09/2023] [Indexed: 08/06/2023]
Abstract
Breast cancer remains the most common cause of cancer death among women. Despite its considerable histological and molecular heterogeneity, those characteristics are not distinguished in most definitions of oligometastatic disease and clinical trials of oligometastatic breast cancer. After an exhaustive review of the literature covering all aspects of oligometastatic breast cancer, 35 experts from the European Organisation for Research and Treatment of Cancer Imaging and Breast Cancer Groups elaborated a Delphi questionnaire aimed at offering consensus recommendations, including oligometastatic breast cancer definition, optimal diagnostic pathways, and clinical trials required to evaluate the effect of diagnostic imaging strategies and metastasis-directed therapies. The main recommendations are the introduction of modern imaging methods in metastatic screening for an earlier diagnosis of oligometastatic breast cancer and the development of prospective trials also considering the histological and molecular complexity of breast cancer. Strategies for the randomisation of imaging methods and therapeutic approaches in different subsets of patients are also addressed.
Collapse
Affiliation(s)
- David Pasquier
- Academic Department of Radiation Oncology, Centre Oscar Lambret, Lille, France; University of Lille and CNRS, Centrale Lille, UMR 9189-CRIStAL, Lille, France.
| | - Luc Bidaut
- College of Science, University of Lincoln, Lincoln, UK
| | - Daniela Elena Oprea-Lager
- Department of Radiology and Nuclear Medicine, Amsterdam University Medical Centers, Vrije Universiteit Amsterdam, Amsterdam, Netherlands
| | - Nandita M deSouza
- The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, Sutton, UK
| | - David Krug
- Department of Radiation Oncology, Universitaetsklinikum Schleswig-Holstein-Campus Kiel, Kiel, Germany
| | - Laurence Collette
- Former European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium
| | - Wolfgang Kunz
- Department of Radiology, University Hospital, LMU Munich, Munich, Germany
| | - Yazid Belkacemi
- AP-HP, Radiation Oncology Department, Henri Mondor University Hospital, Créteil, France; INSERM Unit 955 (-Bio), IMRB, University of Paris-Est (UPEC), Créteil, France
| | - Maria Grazia Bau
- Azienda Ospedaliera Città della Salute e della Scienza di Torino, Ospedale Sant'Anna, Turin, Italy
| | - Caroline Caramella
- Hôpital Marie Lannelongue, Groupe Hospitalier Paris Saint-Joseph, Paris, France
| | - Lioe-Fee De Geus-Oei
- Department of Radiology, Leiden University Medical Center, Leiden, Netherlands; Biomedical Photonic Imaging Group, University of Twente, Enschede, Netherlands; Department of Radiation Science and Technology, Delft University of Technology, Delft, Netherlands
| | - Alex De Caluwé
- Radiotherapy Department, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
| | | | - Olivier Gheysens
- Department of Nuclear Medicine, Institut de Recherche Expérimentale et Clinique (IREC), Cliniques Universitaires Saint-Luc, Institut du Cancer Roi Albert II, UCLouvain, Brussels, Belgium
| | - Ken Herrmann
- Department of Nuclear Medicine, University of Duisburg-Essen, Essen, Germany; German Cancer Consortium (DKTK), University Hospital Essen, Essen, Germany
| | - Isabelle Kindts
- Department of Radiation Oncology, Cancer Centre, General Hospital Groeninge, Kortrijk, Belgium
| | - Michalis Kontos
- National and Kapodistrian University of Athens, Athens, Greece
| | - Sherko Kümmel
- Breast Unit, Kliniken Essen-Mitte, Essen, Germany; Charité - Universitätsmedizin Berlin, Department of Gynecology with Breast Center, Berlin, Germany
| | - Barbro Linderholm
- Department of Oncolgy, Sahlgrenska University Hospital, Gothenburg, Sweden; Institution of Clinical Sciences, Department of Oncology, Sahlgrenska Academy at Gothenburg University, Gothenburg , Sweden
| | | | - Icro Meattini
- Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy; Radiation Oncology Unit, Oncology Department, Azienda Ospedaliero Universitaria Careggi, Florence, Italy
| | - Ann Smeets
- Department of Surgical Oncology, University Hospitals Leuven, KU Leuven, Leuven, Belgium
| | - Orit Kaidar-Person
- Oncology Institute, Sheba Tel Hashomer, Ramat Gan, Israel; Tel-Aviv University, Tel-Aviv, Israel
| | - Philip Poortmans
- Department of Radiation Oncology, Iridium Netwerk, Antwerp, Belgium; University of Antwerp, Antwerp, Belgium
| | - Pelagia Tsoutsou
- Hôpitaux Universitaires de Genève, Site de Cluse-Roseraie, Geneva, Switzerland
| | - Nawale Hajjaji
- Medical Oncology Department, Centre Oscar Lambret, Lille, France; Laboratoire Protéomique, Réponse Inflammatoire, et Spectrométrie De Masse (PRISM), Inserm U1192, Lille, France
| | - Nicola Russell
- Department of Radiotherapy, The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis, Amsterdam, Netherlands
| | | | - Jean-Noël Talbot
- Institut National des Sciences et Techniques Nucléaires, CEA-Saclay, Paris, France
| | - Lale Umutlu
- Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany
| | | | - Joost J C Verhoeff
- Department of Radiotherapy, University Medical Center Utrecht, Utrecht, Netherlands
| | | | - Helle D Zacho
- Department of Nuclear Medicine, Aalborg University Hospital, Aalborg, Denmark
| | - Fatima Cardoso
- Breast Unit, Champalimaud Clinical Centre, Champalimaud Foundation, Lisbon, Portugal
| | - Laure Fournier
- Université Paris Descartes Sorbonne Paris Cité, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Paris, France
| | - Frederieke Van Duijnhoven
- Department of Surgical Oncology, The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis, Amsterdam, Netherlands
| | - Frédéric E Lecouvet
- Department of Radiology, Institut de Recherche Expérimentale et Clinique (IREC), Cliniques Universitaires Saint-Luc, Institut du Cancer Roi Albert II, UCLouvain, Brussels, Belgium
| |
Collapse
|
5
|
Chassagnon G, El Hajjam M, Boussouar S, Revel MP, Khoury R, Ghaye B, Bommart S, Lederlin M, Tran Ba S, De Margerie-Mellon C, Fournier L, Cassagnes L, Ohana M, Jalaber C, Dournes G, Cazeneuve N, Ferretti G, Talabard P, Donciu V, Canniff E, Debray MP, Crutzen B, Charriot J, Rabeau V, Khafagy P, Chocron R, Leonard Lorant I, Metairy L, Ruez-Lantuejoul L, Beaune S, Hausfater P, Truchot J, Khalil A, Penaloza A, Affole T, Brillet PY, Roy C, Pucheux J, Zbili J, Sanchez O, Porcher R. Strategies to safely rule out pulmonary embolism in COVID-19 outpatients: a multicenter retrospective study. Eur Radiol 2023; 33:5540-5548. [PMID: 36826504 PMCID: PMC9951833 DOI: 10.1007/s00330-023-09475-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2022] [Revised: 11/30/2022] [Accepted: 01/24/2023] [Indexed: 02/25/2023]
Abstract
OBJECTIVES The objective was to define a safe strategy to exclude pulmonary embolism (PE) in COVID-19 outpatients, without performing CT pulmonary angiogram (CTPA). METHODS COVID-19 outpatients from 15 university hospitals who underwent a CTPA were retrospectively evaluated. D-Dimers, variables of the revised Geneva and Wells scores, as well as laboratory findings and clinical characteristics related to COVID-19 pneumonia, were collected. CTPA reports were reviewed for the presence of PE and the extent of COVID-19 disease. PE rule-out strategies were based solely on D-Dimer tests using different thresholds, the revised Geneva and Wells scores, and a COVID-19 PE prediction model built on our dataset were compared. The area under the receiver operating characteristics curve (AUC), failure rate, and efficiency were calculated. RESULTS In total, 1369 patients were included of whom 124 were PE positive (9.1%). Failure rate and efficiency of D-Dimer > 500 µg/l were 0.9% (95%CI, 0.2-4.8%) and 10.1% (8.5-11.9%), respectively, increasing to 1.0% (0.2-5.3%) and 16.4% (14.4-18.7%), respectively, for an age-adjusted D-Dimer level. D-dimer > 1000 µg/l led to an unacceptable failure rate to 8.1% (4.4-14.5%). The best performances of the revised Geneva and Wells scores were obtained using the age-adjusted D-Dimer level. They had the same failure rate of 1.0% (0.2-5.3%) for efficiency of 16.8% (14.7-19.1%), and 16.9% (14.8-19.2%) respectively. The developed COVID-19 PE prediction model had an AUC of 0.609 (0.594-0.623) with an efficiency of 20.5% (18.4-22.8%) when its failure was set to 0.8%. CONCLUSIONS The strategy to safely exclude PE in COVID-19 outpatients should not differ from that used in non-COVID-19 patients. The added value of the COVID-19 PE prediction model is minor. KEY POINTS • D-dimer level remains the most important predictor of pulmonary embolism in COVID-19 patients. • The AUCs of the revised Geneva and Wells scores using an age-adjusted D-dimer threshold were 0.587 (95%CI, 0.572 to 0.603) and 0.588 (95%CI, 0.572 to 0.603). • The AUC of COVID-19-specific strategy to rule out pulmonary embolism ranged from 0.513 (95%CI: 0.503 to 0.522) to 0.609 (95%CI: 0.594 to 0.623).
Collapse
Affiliation(s)
- Guillaume Chassagnon
- Radiology Department, Hôpital Cochin, AP-HP, Université Paris Cité, 27 Rue du Faubourg Saint-Jacques, 75014, Paris, France.
| | - Mostafa El Hajjam
- Radiology Department, Hôpital Ambroise Paré, AP-HP, Université Paris Saclay, 9 Av. Charles de Gaulle, 92100, Boulogne-Billancourt, France
| | - Samia Boussouar
- Cardiothoracic Imaging Unit, Hôpital Pitié-Salpêtrière, AP-HP, Sorbonne UniversitéLaboratoire d'imagerie Biomédicale, INSERM, ICAN Institute of Cardiometabolism and Nutrition, 47-83 Boulevard de L'Hôpital, 75013, Paris, France
| | - Marie-Pierre Revel
- Radiology Department, Hôpital Cochin, AP-HP, Université Paris Cité, 27 Rue du Faubourg Saint-Jacques, 75014, Paris, France
| | - Ralph Khoury
- Radiology Department, Hôpital Bichat, AP-HP, Université Paris Cité, 46 Rue Henri Huchard, 75018, Paris, France
| | - Benoît Ghaye
- Radiology Department, Cliniques Universitaires Saint-Luc, 10 Avenue Hippocrate, 1200, Bruxelles, Belgium
| | - Sebastien Bommart
- Radiology Department, Hôpital Arnaud de Villeneuve, PHYMEDEXP - INSERM U1046 - CNRS UMR 9214, Université de Montpellier, 371 Avenue Doyen Gaston Giraud, 34090, Montpellier, France
| | - Mathieu Lederlin
- Radiology Department, Hôpital Pontchaillou, CHU Rennes, Université de Rennes, 2 Rue Henri Le Guilloux, 35000, Rennes, France
| | - Stephane Tran Ba
- Radiology Department, Hôpital Avicenne, AP-HP, Université Sorbonne Paris Nord, 125 Rue de Stalingrad, 93000, Bobigny, France
| | - Constance De Margerie-Mellon
- Radiology Department, Hôpital Saint-Louis, AP-HP, Université Paris Cité, 1 Avenue Claude Vellefaux, 75010, Paris, France
| | - Laure Fournier
- Radiology Department, Hôpital Européen Georges Pompidou, AP-HP, Université Paris Cité, 20 Rue Leblanc, 75015, Paris, France
| | - Lucie Cassagnes
- Radiology Department, CHU Gabriel Montpied, Institut Pascal, TGI, UMR6602 CNRS SIGMA UCA, Université Clermont Auvergne, 58 Rue Montalembert, 63000, Clermont-Ferrand, France
| | - Mickael Ohana
- Radiology Department, Nouvel Hôpital Civil, CHU de Strasbourg, Université de Strasbourg, 1 Place de L'Hôpital, 67000, Strasbourg, France
| | - Carole Jalaber
- Radiology Department, CHU Saint Etienne, Avenue Albert Raimond, 42270, Saint-Priest-en-Jarez, France
| | - Gael Dournes
- Department of Cardio-Thoracic Imaging, Hôpital Haut-Lévêque, CHU de Bordeaux, Université de Bordeaux, INSERM, Centre de Recherche Cardio-Thoracique de Bordeaux, U1045, CIC 1401, 1 Avenue Magellan, 33600, Pessac, France
| | - Nicolas Cazeneuve
- Radiology Department, Hôpital Trousseau, CHU Tours, Avenue de La République, 37170, Chambray-Lès-Tours, France
| | - Gilbert Ferretti
- Radiology Department, CHU de Grenoble Alpes, Université Grenoble Alpes, avenue des Maquis du Grésivaudan, 38700 La Tronche, 38043, Grenoble, France
| | - Pauline Talabard
- Radiology Department, Hôpital Ambroise Paré, AP-HP, Université Paris Saclay, 9 Av. Charles de Gaulle, 92100, Boulogne-Billancourt, France
| | - Victoria Donciu
- Radiology Department, Hôpital Pitié Salpêtrière, AP-HP, Sorbonne Université 47-83 Boulevard de L'Hôpital, 75013, Paris, France
| | - Emma Canniff
- Radiology Department, Hôpital Cochin, AP-HP, Université Paris Cité, 27 Rue du Faubourg Saint-Jacques, 75014, Paris, France
| | - Marie-Pierre Debray
- Radiology Department, Hôpital Bichat, AP-HP, Université Paris Cité, 46 Rue Henri Huchard, 75018, Paris, France
| | - Bernard Crutzen
- Radiology Department, Cliniques Universitaires Saint-Luc, 10 Avenue Hippocrate, 1200, Bruxelles, Belgium
| | - Jeremy Charriot
- Pulmonology Department, Hôpital Arnaud de Villeneuve, CHU Montpellier, 371 Avenue Doyen Gaston Giraud, 34090, Montpellier, France
| | - Valentin Rabeau
- Radiology Department, Hôpital Pontchaillou, CHU Rennes, Université de Rennes, 2 Rue Henri Le Guilloux, 35000, Rennes, France
| | - Philippe Khafagy
- Radiology Department, Hôpital Avicenne, AP-HP, Université Sorbonne Paris Nord, 125 Rue de Stalingrad, 93000, Bobigny, France
| | - Richard Chocron
- Emergency Department, Hôpital Européen Georges Pompidou, AP-HP, Université Paris Cité, 20 Rue Leblanc, 75015, Paris, France
| | - Ian Leonard Lorant
- Radiology Department, Nouvel Hôpital Civil, CHU de Strasbourg, Université de Strasbourg, 1 Place de L'Hôpital, 67000, Strasbourg, France
| | - Loic Metairy
- Radiology Department, Hôpital Trousseau, CHU Tours, Avenue de La République, 37170, Chambray-Lès-Tours, France
| | - Lea Ruez-Lantuejoul
- Radiology Department, CHU de Grenoble Alpes, Université Grenoble Alpes, avenue des Maquis du Grésivaudan, 38700 La Tronche, 38043, Grenoble, France
| | - Sébastien Beaune
- Emergency Department, Hôpital Ambroise Paré, AP-HP, Université Paris Saclay, 9 Avenue Charles de Gaulle, 92100, Boulogne-Billancourt, France
| | - Pierre Hausfater
- Emergency Department, Hôpital Pitié Salpêtrière, AP-HP, GRC-14 BIOSFAST Sorbonne Université, UMR INSERM 1166, IHU ICAN, Sorbonne Université, 47-83 Boulevard de L'Hôpital, 75013, Paris, France
| | - Jennifer Truchot
- Emergency Department, Hôpital Cochin, AP-HP, Université Paris Cité, 27 Rue du Faubourg Saint-Jacques, 75014, Paris, France
| | - Antoine Khalil
- Radiology Department, Hôpital Bichat, AP-HP, Université Paris Cité, 46 Rue Henri Huchard, 75018, Paris, France
| | - Andrea Penaloza
- Services Des Urgences, Cliniques Universitaires Saint-Luc, 10 Avenue Hippocrate, 1200, Bruxelles, Belgium
| | - Thibaut Affole
- Radiology Department, Hôpital Pontchaillou, CHU Rennes, Université de Rennes, 2 Rue Henri Le Guilloux, 35000, Rennes, France
| | - Pierre-Yves Brillet
- Radiology Department, Hôpital Avicenne, AP-HP, UMR U1272 Hypoxie Et Poumon INSERM, Université Sorbonne Paris Nord, 125 Rue de Stalingrad, 93000, Bobigny, France
| | - Catherine Roy
- Radiology Department, Nouvel Hôpital Civil, CHU de Strasbourg, Université de Strasbourg, 1 Place de L'Hôpital, 67000, Strasbourg, France
| | - Julien Pucheux
- Radiology Department, Hôpital Trousseau, CHU Tours, Avenue de La République, 37170, Chambray-Lès-Tours, France
| | - Jordan Zbili
- Radiology Department, Hôpital Pontchaillou, CHU Rennes, Université de Rennes, 2 Rue Henri Le Guilloux, 35000, Rennes, France
| | - Olivier Sanchez
- Pulmonology Department, Hôpital Européen Georges Pompidou, AP-HP, Université Paris Cité, 20 Rue Leblanc, 75015, Paris, France
| | - Raphael Porcher
- Center for Clinical Epidemiology, Hôtel Dieu, AP-HP, Université Paris Cité, 1 Place du Parvis de, 75004, Paris, France
| |
Collapse
|
6
|
Hindman N, Kang S, Fournier L, Lakhman Y, Nougaret S, Reinhold C, Sadowski E, Huang JQ, Ascher S. MRI Evaluation of Uterine Masses for Risk of Leiomyosarcoma: A Consensus Statement. Radiology 2023; 306:e211658. [PMID: 36194109 PMCID: PMC9885356 DOI: 10.1148/radiol.211658] [Citation(s) in RCA: 13] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2021] [Revised: 07/01/2022] [Accepted: 07/11/2022] [Indexed: 01/26/2023]
Abstract
Laparoscopic myomectomy, a common gynecologic operation in premenopausal women, has become heavily regulated since 2014 following the dissemination of unsuspected uterine leiomyosarcoma (LMS) throughout the pelvis of a physician treated for symptomatic leiomyoma. Research since that time suggests a higher prevalence than previously suspected of uterine LMS in resected masses presumed to represent leiomyoma, as high as one in 770 women (0.13%). Though rare, the dissemination of an aggressive malignant neoplasm due to noncontained electromechanical morcellation in laparoscopic myomectomy is a devastating outcome. Gynecologic surgeons' desire for an evidence-based, noninvasive evaluation for LMS is driven by a clear need to avoid such harms while maintaining the availability of minimally invasive surgery for symptomatic leiomyoma. Laparoscopic gynecologists could rely upon the distinction of higher-risk uterine masses preoperatively to plan oncologic surgery (ie, potential hysterectomy) for patients with elevated risk for LMS and, conversely, to safely offer women with no or minimal indicators of elevated risk the fertility-preserving laparoscopic myomectomy. MRI evaluation for LMS may potentially serve this purpose in symptomatic women with leiomyomas. This evidence review and consensus statement defines imaging and disease-related terms to allow more uniform and reliable interpretation and identifies the highest priorities for future research on LMS evaluation.
Collapse
Affiliation(s)
- Nicole Hindman
- From the Departments of Radiology (N.H., S.K.) and Gynecology
(J.Q.H.), NYU Grossman School of Medicine, 660 First Ave, 3rd Floor, New York,
NY 10016; Department of Radiology, Université Paris Cité, AP-HP,
Hôpital Européen Georges Pompidou, PARCC UMRS 970, INSERM, Paris,
France (L.F.); Department of Radiology, Memorial Sloan Kettering Cancer Center,
New York, NY (Y.L.); Department of Radiology, Cancer Institute Montpellier,
Montpellier, France (S.N.); Department of Radiology, McGill University,
Montreal, Quebec, Canada (C.R.); Department of Radiology, University of
Wisconsin School of Medicine and Public Health, Madison, Wis (E.S.); and
Department of Radiology, Georgetown University School of Medicine, Washington,
DC (S.A.)
| | - Stella Kang
- From the Departments of Radiology (N.H., S.K.) and Gynecology
(J.Q.H.), NYU Grossman School of Medicine, 660 First Ave, 3rd Floor, New York,
NY 10016; Department of Radiology, Université Paris Cité, AP-HP,
Hôpital Européen Georges Pompidou, PARCC UMRS 970, INSERM, Paris,
France (L.F.); Department of Radiology, Memorial Sloan Kettering Cancer Center,
New York, NY (Y.L.); Department of Radiology, Cancer Institute Montpellier,
Montpellier, France (S.N.); Department of Radiology, McGill University,
Montreal, Quebec, Canada (C.R.); Department of Radiology, University of
Wisconsin School of Medicine and Public Health, Madison, Wis (E.S.); and
Department of Radiology, Georgetown University School of Medicine, Washington,
DC (S.A.)
| | - Laure Fournier
- From the Departments of Radiology (N.H., S.K.) and Gynecology
(J.Q.H.), NYU Grossman School of Medicine, 660 First Ave, 3rd Floor, New York,
NY 10016; Department of Radiology, Université Paris Cité, AP-HP,
Hôpital Européen Georges Pompidou, PARCC UMRS 970, INSERM, Paris,
France (L.F.); Department of Radiology, Memorial Sloan Kettering Cancer Center,
New York, NY (Y.L.); Department of Radiology, Cancer Institute Montpellier,
Montpellier, France (S.N.); Department of Radiology, McGill University,
Montreal, Quebec, Canada (C.R.); Department of Radiology, University of
Wisconsin School of Medicine and Public Health, Madison, Wis (E.S.); and
Department of Radiology, Georgetown University School of Medicine, Washington,
DC (S.A.)
| | - Yulia Lakhman
- From the Departments of Radiology (N.H., S.K.) and Gynecology
(J.Q.H.), NYU Grossman School of Medicine, 660 First Ave, 3rd Floor, New York,
NY 10016; Department of Radiology, Université Paris Cité, AP-HP,
Hôpital Européen Georges Pompidou, PARCC UMRS 970, INSERM, Paris,
France (L.F.); Department of Radiology, Memorial Sloan Kettering Cancer Center,
New York, NY (Y.L.); Department of Radiology, Cancer Institute Montpellier,
Montpellier, France (S.N.); Department of Radiology, McGill University,
Montreal, Quebec, Canada (C.R.); Department of Radiology, University of
Wisconsin School of Medicine and Public Health, Madison, Wis (E.S.); and
Department of Radiology, Georgetown University School of Medicine, Washington,
DC (S.A.)
| | - Stephanie Nougaret
- From the Departments of Radiology (N.H., S.K.) and Gynecology
(J.Q.H.), NYU Grossman School of Medicine, 660 First Ave, 3rd Floor, New York,
NY 10016; Department of Radiology, Université Paris Cité, AP-HP,
Hôpital Européen Georges Pompidou, PARCC UMRS 970, INSERM, Paris,
France (L.F.); Department of Radiology, Memorial Sloan Kettering Cancer Center,
New York, NY (Y.L.); Department of Radiology, Cancer Institute Montpellier,
Montpellier, France (S.N.); Department of Radiology, McGill University,
Montreal, Quebec, Canada (C.R.); Department of Radiology, University of
Wisconsin School of Medicine and Public Health, Madison, Wis (E.S.); and
Department of Radiology, Georgetown University School of Medicine, Washington,
DC (S.A.)
| | - Caroline Reinhold
- From the Departments of Radiology (N.H., S.K.) and Gynecology
(J.Q.H.), NYU Grossman School of Medicine, 660 First Ave, 3rd Floor, New York,
NY 10016; Department of Radiology, Université Paris Cité, AP-HP,
Hôpital Européen Georges Pompidou, PARCC UMRS 970, INSERM, Paris,
France (L.F.); Department of Radiology, Memorial Sloan Kettering Cancer Center,
New York, NY (Y.L.); Department of Radiology, Cancer Institute Montpellier,
Montpellier, France (S.N.); Department of Radiology, McGill University,
Montreal, Quebec, Canada (C.R.); Department of Radiology, University of
Wisconsin School of Medicine and Public Health, Madison, Wis (E.S.); and
Department of Radiology, Georgetown University School of Medicine, Washington,
DC (S.A.)
| | - Elizabeth Sadowski
- From the Departments of Radiology (N.H., S.K.) and Gynecology
(J.Q.H.), NYU Grossman School of Medicine, 660 First Ave, 3rd Floor, New York,
NY 10016; Department of Radiology, Université Paris Cité, AP-HP,
Hôpital Européen Georges Pompidou, PARCC UMRS 970, INSERM, Paris,
France (L.F.); Department of Radiology, Memorial Sloan Kettering Cancer Center,
New York, NY (Y.L.); Department of Radiology, Cancer Institute Montpellier,
Montpellier, France (S.N.); Department of Radiology, McGill University,
Montreal, Quebec, Canada (C.R.); Department of Radiology, University of
Wisconsin School of Medicine and Public Health, Madison, Wis (E.S.); and
Department of Radiology, Georgetown University School of Medicine, Washington,
DC (S.A.)
| | - Jian Qun Huang
- From the Departments of Radiology (N.H., S.K.) and Gynecology
(J.Q.H.), NYU Grossman School of Medicine, 660 First Ave, 3rd Floor, New York,
NY 10016; Department of Radiology, Université Paris Cité, AP-HP,
Hôpital Européen Georges Pompidou, PARCC UMRS 970, INSERM, Paris,
France (L.F.); Department of Radiology, Memorial Sloan Kettering Cancer Center,
New York, NY (Y.L.); Department of Radiology, Cancer Institute Montpellier,
Montpellier, France (S.N.); Department of Radiology, McGill University,
Montreal, Quebec, Canada (C.R.); Department of Radiology, University of
Wisconsin School of Medicine and Public Health, Madison, Wis (E.S.); and
Department of Radiology, Georgetown University School of Medicine, Washington,
DC (S.A.)
| | - Susan Ascher
- From the Departments of Radiology (N.H., S.K.) and Gynecology
(J.Q.H.), NYU Grossman School of Medicine, 660 First Ave, 3rd Floor, New York,
NY 10016; Department of Radiology, Université Paris Cité, AP-HP,
Hôpital Européen Georges Pompidou, PARCC UMRS 970, INSERM, Paris,
France (L.F.); Department of Radiology, Memorial Sloan Kettering Cancer Center,
New York, NY (Y.L.); Department of Radiology, Cancer Institute Montpellier,
Montpellier, France (S.N.); Department of Radiology, McGill University,
Montreal, Quebec, Canada (C.R.); Department of Radiology, University of
Wisconsin School of Medicine and Public Health, Madison, Wis (E.S.); and
Department of Radiology, Georgetown University School of Medicine, Washington,
DC (S.A.)
| |
Collapse
|
7
|
Bonanno N, Cioni D, Caruso D, Cyran CC, Dinkel J, Fournier L, Gourtsoyianni S, Hoffmann RT, Laghi A, Martincich L, Mayerhoefer ME, Zamboni GA, Sala E, Schlemmer HP, Neri E, D’Anastasi M. Attitudes and perceptions of radiologists towards online (virtual) oncologic multidisciplinary team meetings during the COVID-19 pandemic-a survey of the European Society of Oncologic Imaging (ESOI). Eur Radiol 2023; 33:1194-1204. [PMID: 35986772 PMCID: PMC9391636 DOI: 10.1007/s00330-022-09083-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2022] [Revised: 07/03/2022] [Accepted: 08/04/2022] [Indexed: 02/03/2023]
Abstract
OBJECTIVES To explore radiologists' opinions regarding the shift from in-person oncologic multidisciplinary team meetings (MDTMs) to online MDTMs. To assess the perceived impact of online MDTMs, and to evaluate clinical and technical aspects of online meetings. METHODS An online questionnaire including 24 questions was e-mailed to all European Society of Oncologic Imaging (ESOI) members. Questions targeted the structure and efficacy of online MDTMs, including benefits and limitations. RESULTS A total of 204 radiologists responded to the survey. Responses were evaluated using descriptive statistical analysis. The majority (157/204; 77%) reported a shift to online MDTMs at the start of the pandemic. For the most part, this transition had a positive effect on maintaining and improving attendance. The majority of participants reported that online MDTMs provide the same clinical standard as in-person meetings, and that interdisciplinary discussion and review of imaging data were not hindered. Seventy three of 204 (35.8%) participants favour reverting to in-person MDTs, once safe to do so, while 7/204 (3.4%) prefer a continuation of online MDTMs. The majority (124/204, 60.8%) prefer a combination of physical and online MDTMs. CONCLUSIONS Online MDTMs are a viable alternative to in-person meetings enabling continued timely high-quality provision of care with maintained coordination between specialties. They were accepted by the majority of surveyed radiologists who also favoured their continuation after the pandemic, preferably in combination with in-person meetings. An awareness of communication issues particular to online meetings is important. Training, improved software, and availability of support are essential to overcome technical and IT difficulties reported by participants. KEY POINTS • Majority of surveyed radiologists reported shift from in-person to online oncologic MDT meetings during the COVID-19 pandemic. • The shift to online MDTMs was feasible and generally accepted by the radiologists surveyed with the majority reporting that online MDTMs provide the same clinical standard as in-person meetings. • Most would favour the return to in-person MDTMs but would also accept the continued use of online MDTMs following the end of the current pandemic.
Collapse
Affiliation(s)
- Nathania Bonanno
- Medical Imaging Department, Mater Dei Hospital, University of Malta, Msida, MSD 2090 Malta
| | - Dania Cioni
- Academic Radiology, Department of Translational Research, University of Pisa, Via Roma 67, 56126 Pisa, Italy
| | - Damiano Caruso
- Department of Medical Surgical Sciences and Translational Medicine, Sapienza University of Rome, Sant’Andrea University Hospital, Via di Grottarossa, 1035-1039, 00189 Rome, Italy
| | - Clemens C. Cyran
- Department of Radiology, University Hospital, LMU Munich, Marchioninistr. 15, 81377 Munich, Germany
| | - Julien Dinkel
- Department of Radiology, University Hospital, LMU Munich, Marchioninistr. 15, 81377 Munich, Germany
| | - Laure Fournier
- Radiology Department, Hôpital Européen Georges Pompidou, AP-HP, Université de Paris, 20 Rue Leblanc, F-75015 Paris, France
| | - Sofia Gourtsoyianni
- 1st Department of Radiology, School of Medicine, Areteion Hospital, National and Kapodistrian University of Athens, Athens, Greece
| | - Ralf-Thorsten Hoffmann
- Diagnostische und Interventionelle Radiologie Universitätsklinikum Dresden, TU Dresden, Fetscherstr. 74, 01307 Dresden, Germany
| | - Andrea Laghi
- Department of Medical Surgical Sciences and Translational Medicine, Sapienza University of Rome, Sant’Andrea University Hospital, Via di Grottarossa, 1035-1039, 00189 Rome, Italy
| | - Laura Martincich
- Ospedale Cardinal Massaia Asti, Unit of Radiology, Corso Dante Alighieri, 202, 14100, Asti, Italy
| | - Marius E. Mayerhoefer
- Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, A-1090 Vienna, Austria ,Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065 USA
| | - Giulia A. Zamboni
- Department of Diagnostics and Public Health, Institute of Radiology, University of Verona, Policlinico GB Rossi, P.le LA Scuro 10, 37134 Verona, Italy
| | - Evis Sala
- Department of Radiology Box 218, Cambridge Biomedical Campus Cambridge, Cambridge, CB2 0QQ UK
| | - Heinz-Peter Schlemmer
- Department of Radiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany
| | - Emanuele Neri
- Academic Radiology, Department of Translational Research, University of Pisa, Via Roma 67, 56126 Pisa, Italy
| | - Melvin D’Anastasi
- Medical Imaging Department, Mater Dei Hospital, University of Malta, Msida, MSD 2090 Malta
| |
Collapse
|
8
|
Lacroix M, Aouad T, Feydy J, Biau D, Larousserie F, Fournier L, Feydy A. Artificial intelligence in musculoskeletal oncology imaging: A critical review of current applications. Diagn Interv Imaging 2023; 104:18-23. [PMID: 36270953 DOI: 10.1016/j.diii.2022.10.004] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2022] [Accepted: 10/05/2022] [Indexed: 01/10/2023]
Abstract
Artificial intelligence (AI) is increasingly being studied in musculoskeletal oncology imaging. AI has been applied to both primary and secondary bone tumors and assessed for various predictive tasks that include detection, segmentation, classification, and prognosis. Still, in the field of clinical research, further efforts are needed to improve AI reproducibility and reach an acceptable level of evidence in musculoskeletal oncology. This review describes the basic principles of the most common AI techniques, including machine learning, deep learning and radiomics. Then, recent developments and current results of AI in the field of musculoskeletal oncology are presented. Finally, limitations and future perspectives of AI in this field are discussed.
Collapse
Affiliation(s)
- Maxime Lacroix
- Department of Radiology, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, 75015, France; Université Paris Cité, Faculté de Médecine, Paris, 75006, France; PARCC UMRS 970, INSERM, Paris 75015, France
| | - Theodore Aouad
- Université Paris-Saclay, CentraleSupélec, Inria, Centre for Visual Computing, 91190, Gif-sur-Yvette, France
| | - Jean Feydy
- Université Paris Cité, HeKA team, Inria Paris, Inserm, 75006, Paris, France
| | - David Biau
- Université Paris Cité, Faculté de Médecine, Paris, 75006, France; Department of Orthopedic Surgery, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, 75014, France
| | - Frédérique Larousserie
- Université Paris Cité, Faculté de Médecine, Paris, 75006, France; Department of Pathology, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, 75014, France
| | - Laure Fournier
- Department of Radiology, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Paris, 75015, France; Université Paris Cité, Faculté de Médecine, Paris, 75006, France; PARCC UMRS 970, INSERM, Paris 75015, France
| | - Antoine Feydy
- Université Paris Cité, Faculté de Médecine, Paris, 75006, France; Department of Radiology, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, 75014, France
| |
Collapse
|
9
|
Park SH, Choi JI, Fournier L, Vasey B. Randomized Clinical Trials of Artificial Intelligence in Medicine: Why, When, and How? Korean J Radiol 2022; 23:1119-1125. [PMID: 36447410 PMCID: PMC9747266 DOI: 10.3348/kjr.2022.0834] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2022] [Accepted: 10/30/2022] [Indexed: 11/29/2022] Open
Affiliation(s)
- Seong Ho Park
- Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
| | - Joon-Il Choi
- Department of Radiology, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
| | - Laure Fournier
- Department of Radiology, Université Paris Cité, AP-HP, Hôpital Européen Georges Pompidou, PARCC UMRS 970, INSERM, Paris, France
| | - Baptiste Vasey
- Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK
| |
Collapse
|
10
|
deSouza NM, van der Lugt A, Deroose CM, Alberich-Bayarri A, Bidaut L, Fournier L, Costaridou L, Oprea-Lager DE, Kotter E, Smits M, Mayerhoefer ME, Boellaard R, Caroli A, de Geus-Oei LF, Kunz WG, Oei EH, Lecouvet F, Franca M, Loewe C, Lopci E, Caramella C, Persson A, Golay X, Dewey M, O'Connor JPB, deGraaf P, Gatidis S, Zahlmann G. Standardised lesion segmentation for imaging biomarker quantitation: a consensus recommendation from ESR and EORTC. Insights Imaging 2022; 13:159. [PMID: 36194301 PMCID: PMC9532485 DOI: 10.1186/s13244-022-01287-4] [Citation(s) in RCA: 11] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2022] [Accepted: 08/01/2022] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Lesion/tissue segmentation on digital medical images enables biomarker extraction, image-guided therapy delivery, treatment response measurement, and training/validation for developing artificial intelligence algorithms and workflows. To ensure data reproducibility, criteria for standardised segmentation are critical but currently unavailable. METHODS A modified Delphi process initiated by the European Imaging Biomarker Alliance (EIBALL) of the European Society of Radiology (ESR) and the European Organisation for Research and Treatment of Cancer (EORTC) Imaging Group was undertaken. Three multidisciplinary task forces addressed modality and image acquisition, segmentation methodology itself, and standards and logistics. Devised survey questions were fed via a facilitator to expert participants. The 58 respondents to Round 1 were invited to participate in Rounds 2-4. Subsequent rounds were informed by responses of previous rounds. RESULTS/CONCLUSIONS Items with ≥ 75% consensus are considered a recommendation. These include system performance certification, thresholds for image signal-to-noise, contrast-to-noise and tumour-to-background ratios, spatial resolution, and artefact levels. Direct, iterative, and machine or deep learning reconstruction methods, use of a mixture of CE marked and verified research tools were agreed and use of specified reference standards and validation processes considered essential. Operator training and refreshment were considered mandatory for clinical trials and clinical research. Items with a 60-74% agreement require reporting (site-specific accreditation for clinical research, minimal pixel number within lesion segmented, use of post-reconstruction algorithms, operator training refreshment for clinical practice). Items with ≤ 60% agreement are outside current recommendations for segmentation (frequency of system performance tests, use of only CE-marked tools, board certification of operators, frequency of operator refresher training). Recommendations by anatomical area are also specified.
Collapse
Affiliation(s)
- Nandita M deSouza
- Division of Radiotherapy and Imaging, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, UK.
| | - Aad van der Lugt
- Department of Radiology and Nuclear Medicine, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
| | - Christophe M Deroose
- Nuclear Medicine, University Hospitals Leuven, Leuven, Belgium.,Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium
| | | | - Luc Bidaut
- College of Science, University of Lincoln, Lincoln, Lincoln, LN6 7TS, UK
| | - Laure Fournier
- INSERM, Radiology Department, AP-HP, Hopital Europeen Georges Pompidou, Université de Paris, PARCC, 75015, Paris, France
| | - Lena Costaridou
- School of Medicine, University of Patras, University Campus, Rio, 26 500, Patras, Greece
| | - Daniela E Oprea-Lager
- Department of Radiology and Nuclear Medicine, Amsterdam, UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
| | - Elmar Kotter
- Department of Radiology, University Medical Center Freiburg, Freiburg, Germany
| | - Marion Smits
- Department of Radiology and Nuclear Medicine, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
| | - Marius E Mayerhoefer
- Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria.,Memorial Sloan Kettering Cancer Centre, New York, NY, USA
| | - Ronald Boellaard
- Department of Radiology and Nuclear Medicine, Amsterdam, UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
| | - Anna Caroli
- Department of Biomedical Engineering, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy
| | - Lioe-Fee de Geus-Oei
- Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands.,Biomedical Photonic Imaging Group, University of Twente, Enschede, The Netherlands
| | - Wolfgang G Kunz
- Department of Radiology, University Hospital, LMU Munich, Munich, Germany
| | - Edwin H Oei
- Department of Radiology and Nuclear Medicine, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
| | - Frederic Lecouvet
- Department of Radiology, Institut de Recherche Expérimentale et Clinique (IREC), Cliniques Universitaires Saint Luc, Université Catholique de Louvain (UCLouvain), 10 Avenue Hippocrate, 1200, Brussels, Belgium
| | - Manuela Franca
- Department of Radiology, Centro Hospitalar Universitário do Porto, Instituto de Ciências Biomédicas de Abel Salazar, University of Porto, Porto, Portugal
| | - Christian Loewe
- Division of Cardiovascular and Interventional Radiology, Department for Bioimaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria
| | - Egesta Lopci
- Nuclear Medicine, IRCCS - Humanitas Research Hospital, via Manzoni 56, Rozzano, MI, Italy
| | - Caroline Caramella
- Radiology Department, Hôpital Marie Lannelongue, Institut d'Oncologie Thoracique, Université Paris-Saclay, Le Plessis-Robinson, France
| | - Anders Persson
- Department of Radiology, and Department of Health, Medicine and Caring Sciences, Center for Medical Image Science and Visualization (CMIV), Linköping University, Linköping, Sweden
| | - Xavier Golay
- Queen Square Institute of Neurology, University College London, London, UK
| | - Marc Dewey
- Department of Radiology, Charité Universitätsmedizin Berlin, Berlin, Germany
| | - James P B O'Connor
- Division of Radiotherapy and Imaging, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, UK
| | - Pim deGraaf
- Department of Radiology and Nuclear Medicine, Amsterdam, UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
| | - Sergios Gatidis
- Department of Radiology, University of Tubingen, Tübingen, Germany
| | - Gudrun Zahlmann
- Radiological Society of North America (RSNA), Oak Brook, IL, USA
| | | | | |
Collapse
|
11
|
Delanoy N, Ashton E, Mebarki S, Gisselbrecht M, Nicaise B, Azais H, Koual M, Mongardon ASB, Fournier L, Le Frère-Belda MA, Medioni J, Paillaud E, Oudard S. 544P Feasibility of two different first-line carboplatin plus paclitaxel regimens in elderly women with ovarian cancer: A retrospective study. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.672] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
12
|
Pohyer V, Baudoin D, Fournier L, Rance B. Extraction of Tumor Response Criteria in Semi-Structured Imaging Report. Stud Health Technol Inform 2022; 294:149-150. [PMID: 35612044 DOI: 10.3233/shti220424] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
In this study, we extracted information from 6,376 french CT scan semi-structured text reports evaluating the cancer treatment response using the RECIST methodology. We evaluated the performance against manual annotation of 100 reports and measured the evolution of the presence of information over time. The results show high performances of the extraction as well as trends.
Collapse
Affiliation(s)
| | - David Baudoin
- Hôpital Européen Georges Pompidou, AP-HP, Paris, France
- INSERM, UMRS 1138, Centre de Recherche des Cordeliers, Université Sorbonne-Paris Cité, Paris, France
| | - Laure Fournier
- Hôpital Européen Georges Pompidou, AP-HP, Paris, France
- INSERM, PARCC, Paris, France
- Université de Paris, Paris, France
| | - Bastien Rance
- Hôpital Européen Georges Pompidou, AP-HP, Paris, France
- INSERM, UMRS 1138, Centre de Recherche des Cordeliers, Université Sorbonne-Paris Cité, Paris, France
- Université de Paris, Paris, France
- INRIA, France
| |
Collapse
|
13
|
Roblot V, Giret Y, Mezghani S, Auclin E, Arnoux A, Oudard S, Duron L, Fournier L. Validation of a deep learning segmentation algorithm to quantify the skeletal muscle index and sarcopenia in metastatic renal carcinoma. Eur Radiol 2022; 32:4728-4737. [PMID: 35304638 DOI: 10.1007/s00330-022-08579-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2021] [Revised: 11/23/2021] [Accepted: 12/24/2021] [Indexed: 11/26/2022]
Abstract
OBJECTIVES To validate a deep learning (DL) algorithm for measurement of skeletal muscular index (SMI) and prediction of overall survival in oncology populations. METHODS A retrospective single-center observational study included patients with metastatic renal cell carcinoma between 2007 and 2019. A set of 37 patients was used for technical validation of the algorithm, comparing manual vs DL-based evaluations. Segmentations were compared using mean Dice similarity coefficient (DSC), SMI using concordance correlation coefficient (CCC) and Bland-Altman plots. Overall survivals (OS) were compared using log-rank (Kaplan-Meier) and Mann-Whitney tests. Generalizability of the prognostic value was tested in an independent validation population (N = 87). RESULTS Differences between two manual segmentations (DSC = 0.91, CCC = 0.98 for areas) or manual vs. automated segmentation (DSC = 0.90, CCC = 0.98 for areas, CCC = 0.97 for SMI) had the same order of magnitude. Bland-Altman plots showed a mean difference of -3.33 cm2 [95%CI: -15.98, 9.1] between two manual segmentations, and -3.28 cm2 [95% CI: -14.77, 8.21] for manual vs. automated segmentations. With each method, 20/37 (56%) patients were classified as sarcopenic. Sarcopenic vs. non-sarcopenic groups had statistically different survival curves with median OS of 6.0 vs. 12.5 (p = 0.008) and 6.0 vs. 13.9 (p = 0.014) months respectively for manual and DL methods. In the independent validation population, sarcopenic patients according to DL had a lower OS (10.7 vs. 17.3 months, p = 0.033). CONCLUSION A DL algorithm allowed accurate estimation of SMI compared to manual reference standard. The DL-calculated SMI demonstrated a prognostic value in terms of OS. KEY POINTS • A deep learning algorithm allows accurate estimation of skeletal muscle index compared to a manual reference standard with a concordance correlation coefficient of 0.97. • Sarcopenic patients according to SMI thresholds after segmentation by the deep learning algorithm had statistically significantly lower overall survival compared to non-sarcopenic patients.
Collapse
Affiliation(s)
- Victoire Roblot
- Department of Radiology, Hôpital Européen Georges Pompidou, AP-HP, Université de Paris, PARCC UMRS 970, INSERM, 20 Rue Leblanc, 75015, Paris, France.
| | | | - Sarah Mezghani
- Department of Radiology, Hôpital Européen Georges Pompidou, AP-HP, Université de Paris, PARCC UMRS 970, INSERM, 20 Rue Leblanc, 75015, Paris, France
| | - Edouard Auclin
- Department of Medical Oncology, Hôpital Européen Georges Pompidou, AP-HP, Université de Paris, INSERM CIC1418-EC Clinical Epidemiology Team, Paris, France
| | - Armelle Arnoux
- Informatics and Clinical Research Unit, Department of Biostatistics, Hôpital européen Georges Pompidou, AP-HP, Université de Paris, INSERM CIC1418-EC Clinical Epidemiology Team, Paris, France
| | - Stéphane Oudard
- Department of Medical Oncology, Hôpital Européen Georges Pompidou, AP-HP, Université de Paris, INSERM CIC1418-EC Clinical Epidemiology Team, Paris, France
| | - Loïc Duron
- Department of Radiology, Hôpital Européen Georges Pompidou, AP-HP, Université de Paris, PARCC UMRS 970, INSERM, 20 Rue Leblanc, 75015, Paris, France
- Department of Radiology, Fondation Ophtalmologique Adolphe de Rothschild, Paris, France
| | - Laure Fournier
- Department of Radiology, Hôpital Européen Georges Pompidou, AP-HP, Université de Paris, PARCC UMRS 970, INSERM, 20 Rue Leblanc, 75015, Paris, France
| |
Collapse
|
14
|
Bonmatí LM, Miguel A, Suárez A, Aznar M, Beregi JP, Fournier L, Neri E, Laghi A, França M, Sardanelli F, Penzkofer T, Lambin P, Blanquer I, Menzel M, Seymour K, Figueiras S, Krischak K, Martínez R, Mirsky Y, Yang G, Alberich-Bayarri Á. CHAIMELEON Project: Creation of a Pan-European Repository of Health Imaging Data for the Development of AI-Powered Cancer Management Tools. Front Oncol 2022; 12:742701. [PMID: 35280732 PMCID: PMC8913333 DOI: 10.3389/fonc.2022.742701] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2021] [Accepted: 01/28/2022] [Indexed: 12/13/2022] Open
Abstract
The CHAIMELEON project aims to set up a pan-European repository of health imaging data, tools and methodologies, with the ambition to set a standard and provide resources for future AI experimentation for cancer management. The project is a 4 year long, EU-funded project tackling some of the most ambitious research in the fields of biomedical imaging, artificial intelligence and cancer treatment, addressing the four types of cancer that currently have the highest prevalence worldwide: lung, breast, prostate and colorectal. To allow this, clinical partners and external collaborators will populate the repository with multimodality (MR, CT, PET/CT) imaging and related clinical data. Subsequently, AI developers will enable a multimodal analytical data engine facilitating the interpretation, extraction and exploitation of the information stored at the repository. The development and implementation of AI-powered pipelines will enable advancement towards automating data deidentification, curation, annotation, integrity securing and image harmonization. By the end of the project, the usability and performance of the repository as a tool fostering AI experimentation will be technically validated, including a validation subphase by world-class European AI developers, participating in Open Challenges to the AI Community. Upon successful validation of the repository, a set of selected AI tools will undergo early in-silico validation in observational clinical studies coordinated by leading experts in the partner hospitals. Tool performance will be assessed, including external independent validation on hallmark clinical decisions in response to some of the currently most important clinical end points in cancer. The project brings together a consortium of 18 European partners including hospitals, universities, R&D centers and private research companies, constituting an ecosystem of infrastructures, biobanks, AI/in-silico experimentation and cloud computing technologies in oncology.
Collapse
Affiliation(s)
- Luis Martí Bonmatí
- Medical Imaging Department, La Fe University and Polytechnic Hospital & Biomedical Imaging Research Group Grupo de Investigación Biomédica en Imagen (GIBI2) at La Fe University and Polytechnic Hospital and Health Research Institute, Valencia, Spain,*Correspondence: Luis Martí Bonmatí,
| | - Ana Miguel
- Medical Imaging Department, La Fe University and Polytechnic Hospital & Biomedical Imaging Research Group Grupo de Investigación Biomédica en Imagen (GIBI2) at La Fe University and Polytechnic Hospital and Health Research Institute, Valencia, Spain
| | | | | | | | - Laure Fournier
- Collège des enseignants en radiologie de France, Paris, France
| | - Emanuele Neri
- Diagnostic Radiology 3, Department of Translational Research, University of Pisa, Pisa, Italy
| | - Andrea Laghi
- Medicina Traslazionale e Oncologia, Sant Andrea Sapienza Rome, Rome, Italy
| | - Manuela França
- Department of Radiology, Centro Hospitalar Universitário do Porto, Porto, Portugal
| | - Francesco Sardanelli
- Servizio di Diagnostica per Immagini, “Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Donato, Milanese, Italy
| | - Tobias Penzkofer
- Department of Radiology, CHARITÉ-Universitätsmedizin Berlin, Berlin, Germany
| | - Phillipe Lambin
- Department of Precision Medicine, Maastricht University, Maastricht, Netherlands
| | - Ignacio Blanquer
- Computing Science Department, Universitat Politècnica de València, València, Spain
| | - Marion I. Menzel
- GE Healthcare, München, Germany,Department of Physics, Technical University of Munich, Garching, Germany
| | | | | | - Katharina Krischak
- European Institute for Biomedical Imaging Research, EIBIR gemeinnützige GmbH, Vienna, Austria
| | - Ricard Martínez
- Departamento de Derecho Constitucional, Ciencia Política y Administración, Universitat de València, València, Spain
| | - Yisroel Mirsky
- Software and Information Systems Engineering, Ben-Gurion University of the Negev, Beer Sheva, Israel
| | - Guang Yang
- National Heart and Lung Institute, Imperial College London, London, United Kingdom
| | | |
Collapse
|
15
|
Planquette B, Khider L, Le Berre A, Soudet S, Pernod G, Le Mao R, Besutti M, Gendron N, Yannoutsos A, Smadja DM, Goudot G, Al Kahf S, Mohammedi N, Al Hamoud A, Philippe A, Fournier L, Rance B, Diehl JL, Mirault T, Messas E, Emmerich J, Chocron R, Couturaud F, Ferreti G, Sevestre-Pietri MA, Meneveau N, Chatellier G, Sanchez O. Adjusting D-dimer to lung disease extent to exclude Pulmonary Embolism in COVID-19 patients (Co-LEAD). Thromb Haemost 2022; 122:1888-1898. [PMID: 35144305 PMCID: PMC9626028 DOI: 10.1055/a-1768-4371] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Objective
D-dimer measurement is a safe tool to exclude pulmonary embolism (PE), but its specificity decreases in coronavirus disease 2019 (COVID-19) patients. Our aim was to derive a new algorithm with a specific D-dimer threshold for COVID-19 patients.
Methods
We conducted a French multicenter, retrospective cohort study among 774 COVID-19 patients with suspected PE. D-dimer threshold adjusted to extent of lung damage found on computed tomography (CT) was derived in a patient set (
n
= 337), and its safety assessed in an independent validation set (
n
= 337).
Results
According to receiver operating characteristic curves, in the derivation set, D-dimer safely excluded PE, with one false negative, when using a 900 ng/mL threshold when lung damage extent was <50% and 1,700 ng/mL when lung damage extent was ≥50%. In the derivation set, the algorithm sensitivity was 98.2% (95% confidence interval [CI]: 94.7–100.0) and its specificity 28.4% (95% CI: 24.1–32.3). The negative likelihood ratio (NLR) was 0.06 (95% CI: 0.01–0.44) and the area under the curve (AUC) was 0.63 (95% CI: 0.60–0.67). In the validation set, sensitivity and specificity were 96.7% (95% CI: 88.7–99.6) and 39.2% (95% CI: 32.2–46.1), respectively. The NLR was 0.08 (95% CI; 0.02–0.33), and the AUC did not differ from that of the derivation set (0.68, 95% CI: 0.64–0.72,
p
= 0.097). Using the Co-LEAD algorithm, 76 among 250 (30.4%) COVID-19 patients with suspected PE could have been managed without CT pulmonary angiography (CTPA) and 88 patients would have required two CTs.
Conclusion
The Co-LEAD algorithm could safely exclude PE, and could reduce the use of CTPA in COVID-19 patients. Further prospective studies need to validate this strategy.
Collapse
Affiliation(s)
- Benjamin Planquette
- Innovative Therapies in Haemostasis, INSERM, F-75006 Paris, France; Biosurgical research lab (Carpentier Foundation), F-75015 Paris, France, Université de Paris Faculté de Santé, Paris, France.,Department of Respiratory Medicine, France; Assistance Publique Hôpitaux de Paris.Centre-Université de Paris (APHP-CUP), F-75015 Paris, France., HEGP, Paris, France
| | - Lina Khider
- Physics for Medicine Paris, INSERM U1273, ESPCI Paris, CNRS FRE 2031, F-75011 Paris, France, INSERM, Paris, France.,Biosurgical research lab (Carpentier Foundation), F-75015 Paris, France, Université de Paris, Paris, France.,Vascular medicine department, Georges Pompidou european hospital, Université de Paris, Paris, France
| | - Alice Le Berre
- 3- Department of Radiology, France; Groupe Hospitalier Paris Saint-Joseph, F-75014 Paris, France., GHPSJ, Paris, France
| | - Simon Soudet
- Vascular Medicine, CHU Amiens-Picardie, Amiens, France
| | - Gilles Pernod
- CNRS / TIMC-IMAG UMR 5525 / Themas, Grenoble-Alpes University, France.,Vascular Medicine, University Hospital Grenoble-Alpes, Grenoble, France
| | - Raphael Le Mao
- médecine interne, medecine vasculaire et Pneumologie, Brest University hopsital, Brest, France.,EA 3878, CIC INSERM 1412, Université de Bretagne Occidentale, Brest, France
| | - Matthieu Besutti
- 7- Department of Cardiology, University Hospital, Besançon, EA3920, University of Franche Comté, Besançon, France., CHU Besancon, Besancon, France
| | - Nicolas Gendron
- Hematology, Université Paris decartes, Paris, France.,Hematology, AP-HP, European Hospital Georges Pompidou, France
| | - Alexandra Yannoutsos
- Department of Vascular Medicine, France; INSERM CRESS UMR 1153, F-75005 Paris, France., GHPSJ, Paris, France
| | - David M Smadja
- Hematology, Hopital Europeen Georges Pompidou, Paris, France.,Hematology, Université Paris Descartes, Paris, France
| | - Guillaume Goudot
- Vascular medicine department and Biosurgical research lab (Carpentier Foundation), Georges Pompidou european hospital, Université de Paris, Paris, France
| | - Salma Al Kahf
- Department of Respiratory Medicine, France; Assistance Publique Hôpitaux de Paris.Centre-Université de Paris (APHP-CUP), F-75015 Paris, France., HEGP, Paris, France
| | - Nassim Mohammedi
- Department of Vascular Medicine, Assistance Publique Hôpitaux de Paris.Centre-Université de Paris (APHP-CUP), F-75015 Paris, France, HEGP, Paris, France
| | - Antoine Al Hamoud
- Paris, France; Biosurgical research lab (Carpentier Foundation), F-75015 Paris, France; Department of Respiratory Medicine, France; Assistance Publique Hôpitaux de Paris.Centre-Université de Paris (APHP-CUP), F-75015 Paris, France., HEGP, Paris, France
| | - Aurélien Philippe
- Biosurgical research lab (Carpentier Foundation), F-75015 Paris, France; Department of Haematology, Assistance Publique Hôpitaux de Paris.Centre-Université de Paris (APHP-CUP), F-75015 Paris, France., HEGP, Paris, France
| | - Laure Fournier
- Department of Radiology, Assistance Publique Hôpitaux de Paris.Centre-Université de Paris (APHP-CUP), F-75015 Paris, France., HEGP, Paris, France
| | - Bastien Rance
- Université de Paris, France; Department of Medical Informatics, Assistance Publique Hôpitaux de Paris.Centre-Université de Paris (APHP-CUP), F-75015 Paris, France, Université de Paris Faculté de Santé, Paris, France
| | - Jean-Luc Diehl
- Réanimation médicale - HEGP, Assistance Publique - Hopitaux de Paris, Paris, France
| | - Tristan Mirault
- Vascular medicine department, Georges Pompidou european hospital, Université de Paris, Paris, France
| | - Emmanuel Messas
- Vascular medicine department, Georges Pompidou european hospital, Université de Paris, Paris, France
| | - Joseph Emmerich
- Groupe Hospitalier Paris Saint-Joseph, F-75014 Paris, France; Department of Vascular Medicine, France; INSERM CRESS UMR 1153, F-75005 Paris, France, Université de Paris Faculté de Santé, Paris, France
| | - Richard Chocron
- Emergency department, Georges Pompidou european hospital, Université de Paris, Paris, France
| | - Francis Couturaud
- Department of internal medicine and chest diseases, Brest University Hospital Centre, Brest, France
| | - Gilbert Ferreti
- Department of Radiology, CHU Grenoble-Alpes, CHU Grenoble Alpes, Grenoble, France
| | - Marie-Antoinette Sevestre-Pietri
- 4- Université Picardie Jules Verne EA7516 CHIMERE and Service de médecine vasculaire, CHU Amiens-Picardie, Amiens, France, Université de Picardie Jules Verne, Amiens, France
| | | | | | - Olivier Sanchez
- Université Paris Descartes, Sorbonne Paris Cité, and INSERM UMR S 1140, Paris, FRANCE, Paris, France
| |
Collapse
|
16
|
Fitton I, Noel A, Minassian J, Zerhouni M, Wojak J, Adel M, Fournier L. Technical note: Design and initial evaluation of a novel physical breast phantom to monitor image quality in digital breast tomosynthesis. Med Phys 2022; 49:2355-2365. [DOI: 10.1002/mp.15498] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2021] [Revised: 12/08/2021] [Accepted: 01/17/2022] [Indexed: 11/10/2022] Open
Affiliation(s)
- Isabelle Fitton
- Radiology department AP‐HP Hôpital européen Georges Pompidou Paris F‐75015 France
| | | | | | | | - Julien Wojak
- Aix Marseille Univ CNRS Centrale Marseille Institut Fresnel Marseille France
| | - Mouloud Adel
- Aix Marseille Univ CNRS Centrale Marseille Institut Fresnel Marseille France
| | - Laure Fournier
- Radiology department AP‐HP Hôpital européen Georges Pompidou Paris F‐75015 France
- Université de Paris PARCC INSERM Paris F‐75015 France
| |
Collapse
|
17
|
Fournier L, de Geus-Oei LF, Regge D, Oprea-Lager DE, D’Anastasi M, Bidaut L, Bäuerle T, Lopci E, Cappello G, Lecouvet F, Mayerhoefer M, Kunz WG, Verhoeff JJC, Caruso D, Smits M, Hoffmann RT, Gourtsoyianni S, Beets-Tan R, Neri E, deSouza NM, Deroose CM, Caramella C. Twenty Years On: RECIST as a Biomarker of Response in Solid Tumours an EORTC Imaging Group - ESOI Joint Paper. Front Oncol 2022; 11:800547. [PMID: 35083155 PMCID: PMC8784734 DOI: 10.3389/fonc.2021.800547] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/23/2021] [Accepted: 11/30/2021] [Indexed: 12/15/2022] Open
Abstract
Response evaluation criteria in solid tumours (RECIST) v1.1 are currently the reference standard for evaluating efficacy of therapies in patients with solid tumours who are included in clinical trials, and they are widely used and accepted by regulatory agencies. This expert statement discusses the principles underlying RECIST, as well as their reproducibility and limitations. While the RECIST framework may not be perfect, the scientific bases for the anticancer drugs that have been approved using a RECIST-based surrogate endpoint remain valid. Importantly, changes in measurement have to meet thresholds defined by RECIST for response classification within thus partly circumventing the problems of measurement variability. The RECIST framework also applies to clinical patients in individual settings even though the relationship between tumour size changes and outcome from cohort studies is not necessarily translatable to individual cases. As reproducibility of RECIST measurements is impacted by reader experience, choice of target lesions and detection/interpretation of new lesions, it can result in patients changing response categories when measurements are near threshold values or if new lesions are missed or incorrectly interpreted. There are several situations where RECIST will fail to evaluate treatment-induced changes correctly; knowledge and understanding of these is crucial for correct interpretation. Also, some patterns of response/progression cannot be correctly documented by RECIST, particularly in relation to organ-site (e.g. bone without associated soft-tissue lesion) and treatment type (e.g. focal therapies). These require specialist reader experience and communication with oncologists to determine the actual impact of the therapy and best evaluation strategy. In such situations, alternative imaging markers for tumour response may be used but the sources of variability of individual imaging techniques need to be known and accounted for. Communication between imaging experts and oncologists regarding the level of confidence in a biomarker is essential for the correct interpretation of a biomarker and its application to clinical decision-making. Though measurement automation is desirable and potentially reduces the variability of results, associated technical difficulties must be overcome, and human adjudications may be required.
Collapse
Affiliation(s)
- Laure Fournier
- Imaging Group, European Organisation of Research and Treatment in Cancer (EORTC), Brussels, Belgium
- European Society of Oncologic Imaging (ESOI), European Society of Radiology, Vienna, Austria
- Université de Paris, Assistance Publique–Hôpitaux de Paris (AP-HP), Hopital europeen Georges Pompidou, Department of Radiology, Paris Cardiovascular Research Center (PARCC) Unité Mixte de Recherche (UMRS) 970, Institut national de la santé et de la recherche médicale (INSERM), Paris, France
| | - Lioe-Fee de Geus-Oei
- Imaging Group, European Organisation of Research and Treatment in Cancer (EORTC), Brussels, Belgium
- Department of Radiology, Leiden University Medical Center, Leiden, Netherlands
- Biomedical Photonic Imaging Group, University of Twente, Enschede, Netherlands
| | - Daniele Regge
- European Society of Oncologic Imaging (ESOI), European Society of Radiology, Vienna, Austria
- Department of Surgical Sciences, University of Turin, Turin, Italy
- Radiology Unit, Candiolo Cancer Institute, Fondazione del Piemonte per l’Oncologia-Istituto Di Ricovero e Cura a Carattere Scientifico (FPO-IRCCS), Turin, Italy
| | - Daniela-Elena Oprea-Lager
- Imaging Group, European Organisation of Research and Treatment in Cancer (EORTC), Brussels, Belgium
- Department of Radiology & Nuclear Medicine, Cancer Centre Amsterdam, Amsterdam University Medical Centers [Vrije Universiteit (VU) University], Amsterdam, Netherlands
| | - Melvin D’Anastasi
- European Society of Oncologic Imaging (ESOI), European Society of Radiology, Vienna, Austria
- Medical Imaging Department, Mater Dei Hospital, University of Malta, Msida, Malta
| | - Luc Bidaut
- Imaging Group, European Organisation of Research and Treatment in Cancer (EORTC), Brussels, Belgium
- College of Science, University of Lincoln, Lincoln, United Kingdom
| | - Tobias Bäuerle
- European Society of Oncologic Imaging (ESOI), European Society of Radiology, Vienna, Austria
- Institute of Radiology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany
| | - Egesta Lopci
- Imaging Group, European Organisation of Research and Treatment in Cancer (EORTC), Brussels, Belgium
- Nuclear Medicine Unit, Istituto Di Ricovero e Cura a Carattere Scientifico (IRCCS) – Humanitas Research Hospital, Milan, Italy
| | - Giovanni Cappello
- Department of Surgical Sciences, University of Turin, Turin, Italy
- Radiology Unit, Candiolo Cancer Institute, Fondazione del Piemonte per l’Oncologia-Istituto Di Ricovero e Cura a Carattere Scientifico (FPO-IRCCS), Turin, Italy
| | - Frederic Lecouvet
- Imaging Group, European Organisation of Research and Treatment in Cancer (EORTC), Brussels, Belgium
- Department of Radiology, Institut de Recherche Expérimentale et Clinique (IREC), Cliniques Universitaires Saint Luc, Université Catholique de Louvain (UCLouvain), Brussels, Belgium
| | - Marius Mayerhoefer
- European Society of Oncologic Imaging (ESOI), European Society of Radiology, Vienna, Austria
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, United States
- Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria
| | - Wolfgang G. Kunz
- Imaging Group, European Organisation of Research and Treatment in Cancer (EORTC), Brussels, Belgium
- European Society of Oncologic Imaging (ESOI), European Society of Radiology, Vienna, Austria
- Department of Radiology, University Hospital, Ludwig Maximilian University (LMU) Munich, Munich, Germany
| | - Joost J. C. Verhoeff
- Imaging Group, European Organisation of Research and Treatment in Cancer (EORTC), Brussels, Belgium
- Department of Radiotherapy, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands
| | - Damiano Caruso
- European Society of Oncologic Imaging (ESOI), European Society of Radiology, Vienna, Austria
- Department of Medical-Surgical Sciences and Translational Medicine, Sapienza University of Rome, Rome, Italy
| | - Marion Smits
- Imaging Group, European Organisation of Research and Treatment in Cancer (EORTC), Brussels, Belgium
- Department of Radiology & Nuclear Medicine, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, Netherlands
- Brain Tumour Centre, Erasmus Medical Centre (MC) Cancer Institute, Rotterdam, Netherlands
| | - Ralf-Thorsten Hoffmann
- European Society of Oncologic Imaging (ESOI), European Society of Radiology, Vienna, Austria
- Institute and Policlinic for Diagnostic and Interventional Radiology, University Hospital, Carl-Gustav-Carus Technical University Dresden, Dresden, Germany
| | - Sofia Gourtsoyianni
- European Society of Oncologic Imaging (ESOI), European Society of Radiology, Vienna, Austria
- Department of Radiology, School of Medicine, National and Kapodistrian University of Athens, Areteion Hospital, Athens, Greece
| | - Regina Beets-Tan
- European Society of Oncologic Imaging (ESOI), European Society of Radiology, Vienna, Austria
- Department of Radiology, The Netherlands Cancer Institute, Amsterdam, Netherlands
- School For Oncology and Developmental Biology (GROW) School for Oncology and Developmental Biology, Maastricht University, Maastricht, Netherlands
| | - Emanuele Neri
- European Society of Oncologic Imaging (ESOI), European Society of Radiology, Vienna, Austria
- Diagnostic and Interventional Radiology, Department of Translational Research and of New Surgical and Medical Technologies, University of Pisa, Pisa, Italy
| | - Nandita M. deSouza
- Imaging Group, European Organisation of Research and Treatment in Cancer (EORTC), Brussels, Belgium
- Division of Radiotherapy and Imaging, The Institute of Cancer Research and Royal Marsden National Health Service (NHS) Foundation Trust, London, United Kingdom
- European Imaging Biomarkers Alliance (EIBALL), European Society of Radiology, Vienna, Austria
- Quantitative Imaging Biomarkers Alliance, Radiological Society of North America, Oak Brook, IL, United States
| | - Christophe M. Deroose
- Imaging Group, European Organisation of Research and Treatment in Cancer (EORTC), Brussels, Belgium
- Nuclear Medicine, University Hospitals Leuven, Leuven, Belgium
- Nuclear Medicine & Molecular Imaging, Department of Imaging and Pathology, Katholieke Universiteit (KU) Leuven, Leuven, Belgium
| | - Caroline Caramella
- Imaging Group, European Organisation of Research and Treatment in Cancer (EORTC), Brussels, Belgium
- Radiology Department, Hôpital Marie Lannelongue, Groupe Hospitalier Paris Saint Joseph Centre International des Cancers Thoraciques, Université Paris-Saclay, Le Plessis-Robinson, France
| |
Collapse
|
18
|
Revel MP, Beeker N, Porcher R, Jilet L, Fournier L, Rance B, Chassagnon G, Fontenay M, Sanchez O. What level of D-dimers can safely exclude pulmonary embolism in COVID-19 patients presenting to the emergency department? Eur Radiol 2022; 32:2704-2712. [PMID: 34994845 PMCID: PMC8739682 DOI: 10.1007/s00330-021-08377-9] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2021] [Revised: 09/14/2021] [Accepted: 09/30/2021] [Indexed: 01/19/2023]
Abstract
OBJECTIVES To identify which level of D-dimer would allow the safe exclusion of pulmonary embolism (PE) in COVID-19 patients presenting to the emergency department (ED). METHODS This retrospective study was conducted on the COVID database of Assistance Publique - Hôpitaux de Paris (AP-HP). COVID-19 patients who presented at the ED of AP-HP hospitals between March 1 and May 15, 2020, and had CTPA following D-dimer dosage within 48h of presentation were included. The D-dimer sensitivity, specificity, and positive and negative predictive values were calculated for different D-dimer thresholds, as well as the false-negative and failure rates, and the number of CTPAs potentially avoided. RESULTS A total of 781 patients (mean age 62.0 years, 53.8% men) with positive RT-PCR for SARS-Cov-2 were included and 60 of them (7.7%) had CTPA-confirmed PE. Their median D-dimer level was significantly higher than that of patients without PE (4,013 vs 1,198 ng·mL-1, p < 0.001). Using 500 ng·mL-1, or an age-adjusted cut-off for patients > 50 years, the sensitivity and the NPV were above 90%. With these thresholds, 17.1% and 31.5% of CTPAs could have been avoided, respectively. Four of the 178 patients who had a D-dimer below the age-adjusted cutoff had PE, leading to an acceptable failure rate of 2.2%. Using higher D-dimer cut-offs could have avoided more CTPAs, but would have lowered the sensitivity and increased the failure rate. CONCLUSION The same D-Dimer thresholds as those validated in non-COVID outpatients should be used to safely rule out PE. KEY POINTS • The median D-dimer level was significantly higher in COVID-19 patients with PE as compared to those without PE (4,013 ng·mL-1 vs 1,198 ng·mL-1 respectively, p < 0.001). • Using 500 ng·mL-1, or an age-adjusted D-dimer cut-off to exclude pulmonary embolism, the sensitivity and negative predictive value were above 90%. • Higher cut-offs would lead to a reduction in the sensitivity below 85% and an increase in the failure rate, especially for patients under 50 years.
Collapse
Affiliation(s)
- Marie-Pierre Revel
- Université de Paris, 75006, Paris, France. .,Radiology Department, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Cochin, Service de Radiologie27 rue du Faubourg Saint Jacques, 75014, Paris, France.
| | - Nathanael Beeker
- Université de Paris, 75006, Paris, France.,Assistance Publique-Hôpitaux de Paris (AP-HP), Unité de Recherche Clinique, Hôpital Cochin, Paris, France
| | - Raphael Porcher
- Université de Paris, 75006, Paris, France.,Assistance Publique-Hôpitaux de Paris (AP-HP), Centre d'épidémiologie clinique, Hôtel-Dieu, Paris, France
| | - Léa Jilet
- Assistance Publique-Hôpitaux de Paris (AP-HP), Unité de Recherche Clinique, Hôpital Cochin, Paris, France
| | - Laure Fournier
- Université de Paris, 75006, Paris, France.,Assistance Publique-Hôpitaux de Paris (AP-HP), Service de Radiologie, Hôpital Européen, Georges Pompidou, Paris, France
| | - Bastien Rance
- Université de Paris, 75006, Paris, France.,Assistance Publique-Hôpitaux de Paris (AP-HP), Département d'Informatique Médicale, Biostatistiques Et Santé Publique, Hôpital Européen Georges Pompidou, Paris, France
| | - Guillaume Chassagnon
- Université de Paris, 75006, Paris, France.,Radiology Department, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Cochin, Service de Radiologie27 rue du Faubourg Saint Jacques, 75014, Paris, France
| | - Michaela Fontenay
- Université de Paris, 75006, Paris, France.,Assistance Publique-Hôpitaux de Paris (AP-HP), Service de d'hématologie biologique, Hôpital Cochin, Paris, France.,Institut Cochin INSERM U1016, CNRS UMR8104, Paris, France
| | - Olivier Sanchez
- Université de Paris, 75006, Paris, France.,Assistance Publique-Hôpitaux de Paris (AP-HP), Service de Pneumologie Et Soins Intensifs, Hôpital Européen, Georges Pompidou, INSERM UMRS-1140 Innovative Therapies in Hemostasis and Biosurgical Research Lab (Carpentier Foundation), Paris, France.,F-CRIN INNOVTE, Saint-Etienne, France
| | | |
Collapse
|
19
|
Abstract
The use of artificial intelligence methods for image recognition is one of the most developed branches of the AI field and these technologies are now commonly used in our daily lives. In the field of medical imaging, approaches based on artificial intelligence are particularly promising, with numerous applications and a strong interest in the search for new biomarkers. Here, we will present the general methods used in these approaches as well as the potential areas of application.
Collapse
Affiliation(s)
- Roger Sun
- Gustave Roussy Cancer Campus, université Paris-Saclay, département de Radiothérapie, Inserm U1030, 94805 Villejuif, France.
| | - Eric Deutsch
- Gustave Roussy Cancer Campus, université Paris-Saclay, département de Radiothérapie, Inserm U1030, 94805 Villejuif, France
| | - Laure Fournier
- Hôpital Européen Georges-Pompidou, département de radiologie, 20, rue Leblanc, 75015 Paris, France
| |
Collapse
|
20
|
Benoit L, Koual M, Le Frère-Belda MA, Zerbib J, Fournier L, Nguyen-Xuan HT, Delanoy N, Bentivegna E, Bats AS, Azaïs H. Risks and benefits of systematic lymphadenectomy during interval debulking surgery for advanced high grade serous ovarian cancer. Eur J Surg Oncol 2021; 48:275-282. [PMID: 34753619 DOI: 10.1016/j.ejso.2021.10.027] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2021] [Revised: 10/18/2021] [Accepted: 10/28/2021] [Indexed: 12/14/2022] Open
Abstract
BACKGROUND Lymphadenectomy is debated in patients with ovarian cancer. The aim of our study was to evaluate the impact of lymphadenectomy in patients with high-grade serous ovarian cancer receiving neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS). METHODS A retrospective, unicentric study including all patients undergoing NACT and IDS was carried out from 2005 to 2018. Patients with and without lymphadenectomy were compared in terms of recurrence free survival (RFS), overall survival (OS), and complication rates. RESULTS We included 203 patients. Of these, 133 had a lymphadenectomy (65.5%) and 77 had involved nodes (57.9%). Patients without a lymphadenectomy were older, had a more extensive disease and less complete CRS. No differences were noted between the lymphadenectomy and no lymphadenectomy group concerning 2-year RFS (47.4% and 48.6%, p = 0.87, respectively) and 5-year OS (63.2% versus 58.6%, p = 0.41, respectively). Post-operative complications tended to be more frequent in the lymphadenectomy group (18.57% versus 31.58%, p = 0.09). In patients with a lymphadenectomy, survival was significantly altered if the nodes were involved (positive nodes: 2-year RFS 42.5% and 5-year OS 49.4%, negative nodes: 2-year RFS 60.7% and 5-year OS 82.2%, p = 0.03 and p < 0.001, respectively). CONCLUSION Lymphadenectomy during IDS does not improve survival and increases post-operative complications.
Collapse
Affiliation(s)
- Louise Benoit
- Gynecologic and Breast Oncologic Surgery Department, Georges Pompidou European Hospital, APHP. Centre, Paris, France; Paris University, Faculty of Medicine, Paris, France; INSERM UMR-S 1124, Université de Paris, Centre Universitaire des Saint-Père, Paris, France.
| | - Meriem Koual
- Gynecologic and Breast Oncologic Surgery Department, Georges Pompidou European Hospital, APHP. Centre, Paris, France; Paris University, Faculty of Medicine, Paris, France; INSERM UMR-S 1124, Université de Paris, Centre Universitaire des Saint-Père, Paris, France
| | | | - Jonathan Zerbib
- Radiology Department, Georges Pompidou European Hospital, APHP. Centre, Paris, France
| | - Laure Fournier
- Radiology Department, Georges Pompidou European Hospital, APHP. Centre, Paris, France
| | - Huyen-Thu Nguyen-Xuan
- Gynecologic and Breast Oncologic Surgery Department, Georges Pompidou European Hospital, APHP. Centre, Paris, France; Paris University, Faculty of Medicine, Paris, France
| | - Nicolas Delanoy
- Oncology Department, Georges Pompidou European Hospital, APHP. Centre, Paris, France
| | - Enrica Bentivegna
- Gynecologic and Breast Oncologic Surgery Department, Georges Pompidou European Hospital, APHP. Centre, Paris, France; Paris University, Faculty of Medicine, Paris, France
| | - Anne-Sophie Bats
- Gynecologic and Breast Oncologic Surgery Department, Georges Pompidou European Hospital, APHP. Centre, Paris, France; Paris University, Faculty of Medicine, Paris, France; INSERM UMR-S 1147, Université de Paris, Centre de Recherche des Cordeliers, Paris, France
| | - Henri Azaïs
- Gynecologic and Breast Oncologic Surgery Department, Georges Pompidou European Hospital, APHP. Centre, Paris, France; Paris University, Faculty of Medicine, Paris, France; INSERM UMR-S 1147, Université de Paris, Centre de Recherche des Cordeliers, Paris, France
| |
Collapse
|
21
|
Fournier L, Costaridou L, Bidaut L, Michoux N, Lecouvet FE, de Geus-Oei LF, Boellaard R, Oprea-Lager DE, Obuchowski NA, Caroli A, Kunz WG, Oei EH, O'Connor JPB, Mayerhoefer ME, Franca M, Alberich-Bayarri A, Deroose CM, Loewe C, Manniesing R, Caramella C, Lopci E, Lassau N, Persson A, Achten R, Rosendahl K, Clement O, Kotter E, Golay X, Smits M, Dewey M, Sullivan DC, van der Lugt A, deSouza NM, European Society Of Radiology. Incorporating radiomics into clinical trials: expert consensus endorsed by the European Society of Radiology on considerations for data-driven compared to biologically driven quantitative biomarkers. Eur Radiol 2021; 31:6001-6012. [PMID: 33492473 PMCID: PMC8270834 DOI: 10.1007/s00330-020-07598-8] [Citation(s) in RCA: 52] [Impact Index Per Article: 17.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2020] [Revised: 11/16/2020] [Accepted: 12/03/2020] [Indexed: 02/07/2023]
Abstract
Existing quantitative imaging biomarkers (QIBs) are associated with known biological tissue characteristics and follow a well-understood path of technical, biological and clinical validation before incorporation into clinical trials. In radiomics, novel data-driven processes extract numerous visually imperceptible statistical features from the imaging data with no a priori assumptions on their correlation with biological processes. The selection of relevant features (radiomic signature) and incorporation into clinical trials therefore requires additional considerations to ensure meaningful imaging endpoints. Also, the number of radiomic features tested means that power calculations would result in sample sizes impossible to achieve within clinical trials. This article examines how the process of standardising and validating data-driven imaging biomarkers differs from those based on biological associations. Radiomic signatures are best developed initially on datasets that represent diversity of acquisition protocols as well as diversity of disease and of normal findings, rather than within clinical trials with standardised and optimised protocols as this would risk the selection of radiomic features being linked to the imaging process rather than the pathology. Normalisation through discretisation and feature harmonisation are essential pre-processing steps. Biological correlation may be performed after the technical and clinical validity of a radiomic signature is established, but is not mandatory. Feature selection may be part of discovery within a radiomics-specific trial or represent exploratory endpoints within an established trial; a previously validated radiomic signature may even be used as a primary/secondary endpoint, particularly if associations are demonstrated with specific biological processes and pathways being targeted within clinical trials. KEY POINTS: • Data-driven processes like radiomics risk false discoveries due to high-dimensionality of the dataset compared to sample size, making adequate diversity of the data, cross-validation and external validation essential to mitigate the risks of spurious associations and overfitting. • Use of radiomic signatures within clinical trials requires multistep standardisation of image acquisition, image analysis and data mining processes. • Biological correlation may be established after clinical validation but is not mandatory.
Collapse
Affiliation(s)
- Laure Fournier
- PARCC, INSERM, Radiology Department, AP-HP, Hopital europeen Georges Pompidou, Université de Paris, F-75015, Paris, France
- European Imaging Biomarkers Alliance (EIBALL), European Society of Radiology, Vienna, Austria
- Imaging Group, European Organisation of Research and Treatment in Cancer (EORTC), Brussels, Belgium
| | - Lena Costaridou
- European Imaging Biomarkers Alliance (EIBALL), European Society of Radiology, Vienna, Austria
- School of Medicine, University of Patras, University Campus, Rio, 26 500, Patras, Greece
| | - Luc Bidaut
- Imaging Group, European Organisation of Research and Treatment in Cancer (EORTC), Brussels, Belgium
- College of Science, University of Lincoln, Lincoln, LN6 7TS, UK
| | - Nicolas Michoux
- Imaging Group, European Organisation of Research and Treatment in Cancer (EORTC), Brussels, Belgium
- Department of Radiology, Institut de Recherche Expérimentale et Clinique (IREC), Cliniques Universitaires Saint Luc, Université Catholique de Louvain (UCLouvain), B-1200, Brussels, Belgium
| | - Frederic E Lecouvet
- Imaging Group, European Organisation of Research and Treatment in Cancer (EORTC), Brussels, Belgium
- Department of Radiology, Institut de Recherche Expérimentale et Clinique (IREC), Cliniques Universitaires Saint Luc, Université Catholique de Louvain (UCLouvain), B-1200, Brussels, Belgium
| | - Lioe-Fee de Geus-Oei
- Imaging Group, European Organisation of Research and Treatment in Cancer (EORTC), Brussels, Belgium
- Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands
- Biomedical Photonic Imaging Group, University of Twente, Enschede, The Netherlands
| | - Ronald Boellaard
- European Imaging Biomarkers Alliance (EIBALL), European Society of Radiology, Vienna, Austria
- Department of Radiology & Nuclear Medicine, Cancer Centre Amsterdam, Amsterdam University Medical Centers (VU University), Amsterdam, The Netherlands
- Quantitative Imaging Biomarkers Alliance, Radiological Society of North America, Oak Brook, IL, USA
| | - Daniela E Oprea-Lager
- Imaging Group, European Organisation of Research and Treatment in Cancer (EORTC), Brussels, Belgium
- Department of Radiology & Nuclear Medicine, Cancer Centre Amsterdam, Amsterdam University Medical Centers (VU University), Amsterdam, The Netherlands
| | - Nancy A Obuchowski
- Quantitative Imaging Biomarkers Alliance, Radiological Society of North America, Oak Brook, IL, USA
- Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, USA
| | - Anna Caroli
- European Imaging Biomarkers Alliance (EIBALL), European Society of Radiology, Vienna, Austria
- Department of Biomedical Engineering, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy
| | - Wolfgang G Kunz
- Imaging Group, European Organisation of Research and Treatment in Cancer (EORTC), Brussels, Belgium
- Department of Radiology, University Hospital, LMU Munich, Munich, Germany
| | - Edwin H Oei
- European Imaging Biomarkers Alliance (EIBALL), European Society of Radiology, Vienna, Austria
- Department of Radiology & Nuclear Medicine, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
| | - James P B O'Connor
- European Imaging Biomarkers Alliance (EIBALL), European Society of Radiology, Vienna, Austria
- Division of Cancer Sciences, University of Manchester, Manchester, UK
| | - Marius E Mayerhoefer
- European Imaging Biomarkers Alliance (EIBALL), European Society of Radiology, Vienna, Austria
- Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria
| | - Manuela Franca
- European Imaging Biomarkers Alliance (EIBALL), European Society of Radiology, Vienna, Austria
- Department of Radiology, Centro Hospitalar Universitário do Porto, Instituto de Ciências Biomédicas de Abel Salazar, University of Porto, Porto, Portugal
| | - Angel Alberich-Bayarri
- European Imaging Biomarkers Alliance (EIBALL), European Society of Radiology, Vienna, Austria
- Quantitative Imaging Biomarkers in Medicine (QUIBIM), Valencia, Spain
| | - Christophe M Deroose
- Imaging Group, European Organisation of Research and Treatment in Cancer (EORTC), Brussels, Belgium
- Nuclear Medicine, University Hospitals Leuven, Leuven, Belgium
- Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium
| | - Christian Loewe
- European Imaging Biomarkers Alliance (EIBALL), European Society of Radiology, Vienna, Austria
- Division of Cardiovascular and Interventional Radiology, Dept. for Bioimaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria
| | - Rashindra Manniesing
- European Imaging Biomarkers Alliance (EIBALL), European Society of Radiology, Vienna, Austria
- Department of Radiology and Nuclear Medicine, Radboud University Medical Center, 6525 GA, Nijmegen, The Netherlands
| | - Caroline Caramella
- Imaging Group, European Organisation of Research and Treatment in Cancer (EORTC), Brussels, Belgium
- Radiology Department, Hôpital Marie Lannelongue, Institut d'Oncologie Thoracique, Université Paris-Saclay, Le Plessis-Robinson, France
| | - Egesta Lopci
- Imaging Group, European Organisation of Research and Treatment in Cancer (EORTC), Brussels, Belgium
- Nuclear Medicine, Humanitas Clinical and Research Hospital - IRCCS, Rozzano, MI, Italy
| | - Nathalie Lassau
- European Imaging Biomarkers Alliance (EIBALL), European Society of Radiology, Vienna, Austria
- Imaging Group, European Organisation of Research and Treatment in Cancer (EORTC), Brussels, Belgium
- Quantitative Imaging Biomarkers Alliance, Radiological Society of North America, Oak Brook, IL, USA
- Imaging Department, Gustave Roussy Cancer Campus Grand, Paris, UMR 1281, INSERM, CNRS, CEA, Universite Paris-Saclay, Saint-Aubin, France
| | - Anders Persson
- European Imaging Biomarkers Alliance (EIBALL), European Society of Radiology, Vienna, Austria
- Department of Radiology, and Department of Health, Medicine and Caring Sciences, Center for Medical Image Science and Visualization (CMIV), Linköping University, Linköping, Sweden
| | - Rik Achten
- European Imaging Biomarkers Alliance (EIBALL), European Society of Radiology, Vienna, Austria
- Department of Radiology and Medical Imaging, Ghent University Hospital, Gent, Belgium
| | - Karen Rosendahl
- European Imaging Biomarkers Alliance (EIBALL), European Society of Radiology, Vienna, Austria
- Department of Radiology, University Hospital of North Norway, Tromsø, Norway
| | - Olivier Clement
- PARCC, INSERM, Radiology Department, AP-HP, Hopital europeen Georges Pompidou, Université de Paris, F-75015, Paris, France
- European Imaging Biomarkers Alliance (EIBALL), European Society of Radiology, Vienna, Austria
| | - Elmar Kotter
- European Imaging Biomarkers Alliance (EIBALL), European Society of Radiology, Vienna, Austria
- Department of Radiology, University Medical Center Freiburg, Freiburg, Germany
| | - Xavier Golay
- European Imaging Biomarkers Alliance (EIBALL), European Society of Radiology, Vienna, Austria
- Quantitative Imaging Biomarkers Alliance, Radiological Society of North America, Oak Brook, IL, USA
- Queen Square Institute of Neurology, University College London, London, UK
| | - Marion Smits
- European Imaging Biomarkers Alliance (EIBALL), European Society of Radiology, Vienna, Austria
- Imaging Group, European Organisation of Research and Treatment in Cancer (EORTC), Brussels, Belgium
- Department of Radiology & Nuclear Medicine, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
| | - Marc Dewey
- European Imaging Biomarkers Alliance (EIBALL), European Society of Radiology, Vienna, Austria
- Department of Radiology, Charité Universitätsmedizin Berlin, Berlin, Germany
| | - Daniel C Sullivan
- European Imaging Biomarkers Alliance (EIBALL), European Society of Radiology, Vienna, Austria
- Quantitative Imaging Biomarkers Alliance, Radiological Society of North America, Oak Brook, IL, USA
- Dept. of Radiology, Duke University, 311 Research Dr, Durham, NC, 27710, USA
| | - Aad van der Lugt
- European Imaging Biomarkers Alliance (EIBALL), European Society of Radiology, Vienna, Austria
- Department of Radiology & Nuclear Medicine, Erasmus MC, University Medical Center, Rotterdam, The Netherlands
| | - Nandita M deSouza
- European Imaging Biomarkers Alliance (EIBALL), European Society of Radiology, Vienna, Austria.
- Imaging Group, European Organisation of Research and Treatment in Cancer (EORTC), Brussels, Belgium.
- Quantitative Imaging Biomarkers Alliance, Radiological Society of North America, Oak Brook, IL, USA.
- Division of Radiotherapy and Imaging, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, UK.
| | | |
Collapse
|
22
|
Jevnikar M, Sanchez O, Chocron R, Andronikof M, Raphael M, Meyrignac O, Fournier L, Montani D, Planquette B, Soudani M, Boucly A, Pichon J, Preda M, Beurnier A, Bulifon S, Seferian A, Jaïs X, Sitbon O, Savale L, Humbert M, Parent F. Prevalence of pulmonary embolism in patients with COVID-19 at the time of hospital admission. Eur Respir J 2021; 58:13993003.00116-2021. [PMID: 33692122 PMCID: PMC7947356 DOI: 10.1183/13993003.00116-2021] [Citation(s) in RCA: 30] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2020] [Accepted: 02/28/2021] [Indexed: 01/30/2023]
Abstract
A high prevalence of venous thromboembolism (VTE) has been reported during intensive care unit (ICU) hospitalisation in patients with severe coronavirus disease 2019 (COVID-19) [1, 2]. In most cases, the diagnosis of pulmonary embolism (PE) was incidental as patients underwent computed tomography pulmonary angiography (CTPA) for aggravation of their respiratory condition. Higher mortality is also described in patients with high D-dimer levels suggesting that VTE complication may contribute to unfavourable prognosis [3, 4]. Even though, prevalence of thromboembolic complications during ICU hospitalisation seems to be high, the prevalence of pulmonary embolism at hospital admission for COVID-19 is unknown and may be underestimated. There is a high prevalence of pulmonary embolism in patients with COVID-19 at the time of hospital admissionhttps://bit.ly/3reaLjv
Collapse
Affiliation(s)
- Mitja Jevnikar
- Université Paris-Saclay, Faculty of Medicine, Le Kremlin-Bicêtre, France.,INSERM UMR_S 999, Le Kremlin-Bicêtre, France.,AP-HP, Service de Pneumologie et soins intensifs respiratoires, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
| | - Olivier Sanchez
- AP-HP, Service de Pneumologie et Soins Intensifs, Hôpital Européen Georges Pompidou, Paris, France.,INSERM UMR-S 1140; Paris, France and INNOVTE, St-Etienne, France.,Université Paris Descartes, Faculty of Medicine, Paris, France
| | - Richard Chocron
- Université Paris Descartes, Faculty of Medicine, Paris, France.,AP-HP, Service d'Urgence, Hôpital Européen Georges Pompidou, Paris, France
| | - Marc Andronikof
- Université Paris-Saclay, Faculty of Medicine, Le Kremlin-Bicêtre, France.,AP-HP, Service d'Urgenc, Hôpital Antoine Béclère, Clamart, France
| | - Maurice Raphael
- Université Paris-Saclay, Faculty of Medicine, Le Kremlin-Bicêtre, France.,AP-HP, Service d'Urgence, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
| | - Olivier Meyrignac
- Université Paris-Saclay, Faculty of Medicine, Le Kremlin-Bicêtre, France.,AP-HP, Service de Radiologie, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
| | - Laure Fournier
- Université Paris Descartes, Faculty of Medicine, Paris, France.,AP-HP, Service de Radiologie, Hôpital Européen Georges Pompidou, Paris, France
| | - David Montani
- Université Paris-Saclay, Faculty of Medicine, Le Kremlin-Bicêtre, France.,INSERM UMR_S 999, Le Kremlin-Bicêtre, France.,AP-HP, Service de Pneumologie et soins intensifs respiratoires, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
| | - Benjamin Planquette
- AP-HP, Service de Pneumologie et Soins Intensifs, Hôpital Européen Georges Pompidou, Paris, France.,INSERM UMR-S 1140; Paris, France and INNOVTE, St-Etienne, France.,Université Paris Descartes, Faculty of Medicine, Paris, France
| | - Mary Soudani
- Université Paris-Saclay, Faculty of Medicine, Le Kremlin-Bicêtre, France.,AP-HP, Service de gériatrie, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
| | - Athénaïs Boucly
- Université Paris-Saclay, Faculty of Medicine, Le Kremlin-Bicêtre, France.,INSERM UMR_S 999, Le Kremlin-Bicêtre, France.,AP-HP, Service de Pneumologie et soins intensifs respiratoires, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
| | - Jeremie Pichon
- Université Paris-Saclay, Faculty of Medicine, Le Kremlin-Bicêtre, France.,INSERM UMR_S 999, Le Kremlin-Bicêtre, France.,AP-HP, Service de Pneumologie et soins intensifs respiratoires, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
| | - Mariana Preda
- Université Paris-Saclay, Faculty of Medicine, Le Kremlin-Bicêtre, France.,INSERM UMR_S 999, Le Kremlin-Bicêtre, France.,AP-HP, Service de Pneumologie et soins intensifs respiratoires, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
| | - Antoine Beurnier
- Université Paris-Saclay, Faculty of Medicine, Le Kremlin-Bicêtre, France.,INSERM UMR_S 999, Le Kremlin-Bicêtre, France.,AP-HP, Service de physiologie et d'explorations fonctionnelles respiratoires (CRISALIS/F-CRIN network), Hôpital Bicêtre, Le Kremlin-Bicêtre, France
| | - Sophie Bulifon
- Université Paris-Saclay, Faculty of Medicine, Le Kremlin-Bicêtre, France.,INSERM UMR_S 999, Le Kremlin-Bicêtre, France.,AP-HP, Service de Pneumologie et soins intensifs respiratoires, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
| | - Andrei Seferian
- Université Paris-Saclay, Faculty of Medicine, Le Kremlin-Bicêtre, France.,INSERM UMR_S 999, Le Kremlin-Bicêtre, France.,AP-HP, Service de Pneumologie et soins intensifs respiratoires, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
| | - Xavier Jaïs
- Université Paris-Saclay, Faculty of Medicine, Le Kremlin-Bicêtre, France.,INSERM UMR_S 999, Le Kremlin-Bicêtre, France.,AP-HP, Service de Pneumologie et soins intensifs respiratoires, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
| | - Olivier Sitbon
- Université Paris-Saclay, Faculty of Medicine, Le Kremlin-Bicêtre, France.,INSERM UMR_S 999, Le Kremlin-Bicêtre, France.,AP-HP, Service de Pneumologie et soins intensifs respiratoires, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
| | - Laurent Savale
- Université Paris-Saclay, Faculty of Medicine, Le Kremlin-Bicêtre, France.,INSERM UMR_S 999, Le Kremlin-Bicêtre, France.,AP-HP, Service de Pneumologie et soins intensifs respiratoires, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
| | - Marc Humbert
- Université Paris-Saclay, Faculty of Medicine, Le Kremlin-Bicêtre, France.,INSERM UMR_S 999, Le Kremlin-Bicêtre, France.,AP-HP, Service de Pneumologie et soins intensifs respiratoires, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
| | - Florence Parent
- Université Paris-Saclay, Faculty of Medicine, Le Kremlin-Bicêtre, France.,INSERM UMR_S 999, Le Kremlin-Bicêtre, France.,AP-HP, Service de Pneumologie et soins intensifs respiratoires, Hôpital Bicêtre, Le Kremlin-Bicêtre, France
| |
Collapse
|
23
|
Benoit L, Zerbib J, Koual M, Nguyen-Xuan HT, Delanoy N, Le Frère-Belda MA, Bentivegna E, Bats AS, Fournier L, Azaïs H. What can we learn from the 10 mm lymph node size cut-off on the CT in advanced ovarian cancer at the time of interval debulking surgery? Gynecol Oncol 2021; 162:667-673. [PMID: 34217542 DOI: 10.1016/j.ygyno.2021.06.025] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2021] [Revised: 06/23/2021] [Accepted: 06/25/2021] [Indexed: 12/28/2022]
Abstract
INTRODUCTION The benefit of a systematic lymphadenectomy is still debated in patients undergoing neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) in ovarian cancer (OC). The objective of this study was to evaluate the predictive value of the pre-NACT and post-NACT CT in predicting definitive histological lymph node involvement. The prognostic value of a positive node on the CT was also assessed. MATERIEL AND METHODS A retrospective, unicentric cohort study was performed including all patients with ovarian cancer who underwent NACT and IDS with a lymphadenectomy between 2005 and 2018. CT were analyzed blinded to pathology, and nodes with small axis ≥ 10 mm on CT were considered positive. Sensitivity (Se), specificity (Sp), and negative (NPV) and positive predictive values (PPV) and their CI95% were calculated. The 2-year recurrence free survival (RFS) and 5-year overall survival (OS) was compared. RESULTS 158 patients were included, among which 92 (58%) had histologically positive lymph nodes. CT had a Se, Sp, NPV and PPV of 35%, 82%, 47% and 73% before NACT and 20%, 97%, 47% and 91% after NACT, respectively. Patients with nodes considered positive had a non-significant lower 2-year RFS and 5-year OS on the pre-NACT and post-NACT CT. Patients at 'high risk' (nodes stayed positive on the CT or became positive after NACT) also had a non-significant lower 2-year RFS and 5-year OS. CONCLUSION Presence of enlarged lymph nodes on CT is a weak indicator of lymph node involvement in patients with advanced ovarian cancer undergoing NACT. However, it could be used to assess prognosis.
Collapse
Affiliation(s)
- Louise Benoit
- Gynecologic and Breast Oncologic Surgery Department, European Georges-Pompidou Hospital, APHP Centre, Paris, France; Paris University, Faculty of Medicine, Paris, France; INSERM UMR-S 1124, Université de Paris, Centre Universitaire des Saint-Père, Paris, France.
| | - Jonathan Zerbib
- Université de Paris, AP-HP, Hôpital Européen Georges Pompidou, Department of Radiology, PARCC UMRS 970, INSERM, Paris, France
| | - Meriem Koual
- Gynecologic and Breast Oncologic Surgery Department, European Georges-Pompidou Hospital, APHP Centre, Paris, France; Paris University, Faculty of Medicine, Paris, France; INSERM UMR-S 1124, Université de Paris, Centre Universitaire des Saint-Père, Paris, France
| | - Huyen-Thu Nguyen-Xuan
- Gynecologic and Breast Oncologic Surgery Department, European Georges-Pompidou Hospital, APHP Centre, Paris, France
| | - Nicolas Delanoy
- Oncology Department, Georges Pompidou European Hospital, APHP. Centre, Paris, France
| | | | - Enrica Bentivegna
- Gynecologic and Breast Oncologic Surgery Department, European Georges-Pompidou Hospital, APHP Centre, Paris, France
| | - Anne-Sophie Bats
- Gynecologic and Breast Oncologic Surgery Department, European Georges-Pompidou Hospital, APHP Centre, Paris, France; Paris University, Faculty of Medicine, Paris, France; INSERM UMR-S 1147, Université de Paris, Centre de Recherche des Cordeliers, Paris, France
| | - Laure Fournier
- Université de Paris, AP-HP, Hôpital Européen Georges Pompidou, Department of Radiology, PARCC UMRS 970, INSERM, Paris, France
| | - Henri Azaïs
- Gynecologic and Breast Oncologic Surgery Department, European Georges-Pompidou Hospital, APHP Centre, Paris, France; Paris University, Faculty of Medicine, Paris, France; INSERM UMR-S 1147, Université de Paris, Centre de Recherche des Cordeliers, Paris, France
| |
Collapse
|
24
|
Revel MP, Boussouar S, de Margerie-Mellon C, Saab I, Lapotre T, Mompoint D, Chassagnon G, Milon A, Lederlin M, Bennani S, Molière S, Debray MP, Bompard F, Dangeard S, Hani C, Ohana M, Bommart S, Jalaber C, El Hajjam M, Petit I, Fournier L, Khalil A, Brillet PY, Bellin MF, Redheuil A, Rocher L, Bousson V, Rousset P, Grégory J, Deux JF, Dion E, Valeyre D, Porcher R, Jilet L, Abdoul H. Study of Thoracic CT in COVID-19: The STOIC Project. Radiology 2021; 301:E361-E370. [PMID: 34184935 PMCID: PMC8267782 DOI: 10.1148/radiol.2021210384] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Background There are conflicting data regarding the diagnostic performance of Chest computed tomography (CT) for COVID-19 pneumonia. Disease extent on CT has been reported to influence prognosis. Purpose To create a large publicly available dataset and assess the diagnostic and prognostic value of CT in COVID-19 pneumonia. Materials and Methods This multicenter observational retrospective cohort study (ClinicalTrials.gov: NCT04355507) involved 20 French university hospitals. Eligible subjects presented at the emergency departments of the hospitals involved between March 1st and April 30th, 2020 and underwent both thoracic CT and RT-PCR for suspected COVID-19 pneumonia. CT images were read blinded to initial reports, RT-PCR, demographic characteristics, clinical symptoms, and outcome. Readers classified CT scans as positive or negative for COVID-19, based on criteria published by the French Society of Radiology. Multivariable logistic regression was used to develop a model predicting severe outcome (intubation or death) at 1-month follow-up in subjects positive for both RT-PCR and CT, using clinical and radiological features. Results Of 10,930 subjects screened for eligibility, 10,735 (median age 65 years, interquartile range, 51-77 years; 6,147 men) were included and 6,448 (60.0%) had a positive RT-PCR result. With RT-PCR as reference, the sensitivity and specificity and CT were 80.2% (95%CI: 79.3, 81.2) and 79.7% (95%CI: 78.5, 80.9), respectively with strong agreement between junior and senior radiologists (Gwet's AC1 coefficient: 0.79) Of all the variables analysed, the extent of pneumonia on CT (OR 3.25, 95%CI: 2.71, 3.89) was the best predictor of severe outcome at one month. A score based solely on clinical variables predicted a severe outcome with an AUC of 0.64 (95%CI: 0.62, 0.66), improving to 0.69 (95%CI: 0.6, 0.71) when it also included the extent of pneumonia and coronary calcium score on CT. Conclusion Using pre-defined criteria, CT reading is not influenced by reader's experience and helps predict the outcome at one month. Published under a CC BY 4.0 license. See also the editorial by Rubin.
Collapse
Affiliation(s)
- Marie-Pierre Revel
- Université de Paris, APHP, Hôpital Cochin, Dept of Radiology, Paris, France
| | - Samia Boussouar
- Sorbonne Université, APHP, Hôpital Pitié Salpétrière, Dept of Radiology, Paris, France
| | | | - Inès Saab
- Université de Paris, APHP, Hôpital Cochin, Dept of Radiology, Paris, France
| | - Thibaut Lapotre
- Université Rennes1, Hôpital Pontchaillou, Dept of Radiology, Rennes, France
| | - Dominique Mompoint
- Université Paris-Saclay, APHP, Hôpital Raymond Poincaré, Dept of Radiology, Garches, France
| | | | - Audrey Milon
- Sorbonne Université, APHP, Hôpital Tenon, Dept of Radiology, Paris, France
| | - Mathieu Lederlin
- Université Rennes1, Hôpital Pontchaillou, Dept of Radiology, Rennes, France
| | - Souhail Bennani
- Université de Paris, APHP, Hôpital Cochin, Dept of Radiology, Paris, France
| | - Sébastien Molière
- Université de Strasbourg, Hôpital de Hautepierre, Dept of Radiology, Strasbourg, France
| | | | - Florian Bompard
- Université de Paris, APHP, Hôpital Cochin, Dept of Radiology, Paris, France
| | - Severine Dangeard
- Université de Paris, APHP, Hôpital Cochin, Dept of Radiology, Paris, France
| | - Chahinez Hani
- Université de Paris, APHP, Hôpital Cochin, Dept of Radiology, Paris, France
| | - Mickaël Ohana
- Université de Strasbourg, Nouvel Hôpital Civil, Dept of Radiology, Strasbourg, France
| | - Sébastien Bommart
- Université de Montpellier, Hôpital Arnaud de Villeneuve, Dept of Radiology, Montpellier France
| | - Carole Jalaber
- Université de Paris, APHP, Hôpital Cochin, Dept of Radiology, Paris, France
| | - Mostafa El Hajjam
- Université Paris-Saclay, APHP, Hôpital Ambroise Paré, Dept of Radiology, Boulogne, France
| | - Isabelle Petit
- Université de Lorraine, Hôpital Brabois, Dept of Radiology, Vandoeuvre, France
| | - Laure Fournier
- Université de Paris, APHP, Hôpital Européen Georges Pompidou, Dept of Radiology, INSERM U970, PARCC, Paris, France
| | - Antoine Khalil
- Université de Paris, APHP, Hôpital Bichat, Dept of Radiology, Paris, France
| | - Pierre-Yves Brillet
- Sorbonne Université, APHP, Hôpital Avicenne, Dept of Radiology, Bobigny, France
| | - Marie-France Bellin
- Université Paris-Saclay, APHP, Hôpital Bicêtre, Dept of Radiology, Le Kremlin-Bicêtre, France
| | - Alban Redheuil
- Sorbonne Université, APHP, Hôpital Pitié Salpétrière, Dept of Radiology, Paris, France
| | - Laurence Rocher
- Université Paris-Saclay, APHP, Hôpital Antoine Béclère, Dept of Radiology, Clamart, France
| | - Valérie Bousson
- Université de Paris, APHP, Hôpital Lariboisière, Dept of Radiology, Paris, France
| | - Pascal Rousset
- Université Claude Bernard Lyon 1, Hospices Civils de Lyon, Hôpital Lyon Sud, Dept of Radiology, Pierre-Benite, France
| | - Jules Grégory
- Université de Paris, APHP, Hôpital Beaujon, Dept of Radiology, Clichy, France
| | - Jean-François Deux
- Université Paris Est, APHP, Dept of Radiology, Hôpital Henri Mondor, Créteil, France
| | - Elisabeth Dion
- Université de Paris, APHP, Hôtel-Dieu, Dept of Radiology, Paris, France
| | - Dominique Valeyre
- Sorbonne Université, APHP, Hôpital Avicenne, Dept of Pneumology, Bobigny, INSERM UMR 1272, France
| | - Raphael Porcher
- Université de Paris, APHP, Hôtel-Dieu, Dept of Clinical Epidemiology, Paris, France
| | - Léa Jilet
- Université de Paris APHP, Clinical Research Unit Paris Centre, Paris, France
| | - Hendy Abdoul
- Université de Paris APHP, Clinical Research Unit Paris Centre, Paris, France
| |
Collapse
|
25
|
Nicaise B, Mebarki S, Gisselbrecht M, Ashton E, Azais H, Koual M, Bats AS, Fournier L, Le Frère - Belda MA, Medioni J, Paillaud E, Oudard S, Delanoy N. Feasibility of an adapted schedule of carboplatin plus paclitaxel in elderly women with advanced ovarian cancer: A retrospective cohort. J Clin Oncol 2021. [DOI: 10.1200/jco.2021.39.15_suppl.5546] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5546 Background: The EWOC-1 trial compared Carboplatin monotherapy (C mono) to two different Carboplatin + Paclitaxel (CP) regimens (weekly or 3-weekly) in vulnerable elderly patients treated for advanced ovarian cancers (OC). This study was closed prematurely because of a worse outcome in the C mono group. Both CP regimens were equivalent in terms of feasibility and efficacy with different toxicity profiles. Optimal CP regimen in elderly patient is still unknown. Here we propose a study of another adapted regimen of CP (aCP) performed in elderly patients in our institution. Methods: We retrospectively analyzed OC patients ≥ 70 years who received a Carboplatin AUC 4-5 d1q3week + Paclitaxel 80 mg/m² d1-d8 q3week regimen between 2015 and 2019. Primary endpoint was treatment feasibility according to the EWOC-1 standard: completion of 6 courses of chemotherapy without early stopping for disease progression, death or unacceptable toxicity (adverse event (AE) related to chemotherapy or treatment procedure leading either to early treatment stopping, to an unplanned hospital admission or to death or to a dose delay lasting more than 14 days or more than 2 dose reductions). Results: We identified 36 pts with a median age of 79 years (table). All patient but one had an ONCODAGE-G8 score ≤ 14, 30.6% of patients had a comorbidity Charlson’s index > 4 and 52.5% had an albumin rate < 35 g/L. The feasibility endpoint was met in 58.3% of patients (IC95% = [25.6; 57.8]). Main causes of treatment failure (TF) were early discontinuation because of toxicity in 6 patients (16.7%) and progressive disease in 3 patients (8.33%). Median PFS was 35.3 months (IC95% = [22.7; NR]) and median OS was 62.1 months (IC95% = [31.4.0; NR]). The most frequent AE were asthenia (all grades = 94.4%, grade 3-4 = 13.9%), anemia (all grades = 94.4%, grade 3-4 = 27.8%), neutropenia (all grades = 66.7%, grade 3-4 = 38.9%) and neuropathy sensory (all grades = 61.1%, no grade 3-4). Non high-grade-serous histological type and a poor Charlson’s score were associated with a higher rate of TF (100% and 63.6%, respectively). Conclusions: These results are consistent with the findings of the EWOC-1 trial in both CP regimens and suggest that aCP could be non-inferior with an acceptable toxicity profile. Further prospective and comparative studies are mandatory to confirm this trend and to better identify predictive factors of TF in OC elderly patients.[Table: see text]
Collapse
Affiliation(s)
- Benjamin Nicaise
- Department of Medical Oncology, European Georges-Pompidou Hospital, APHP. Centre, France; Paris University, Faculty of Medicine, Paris, France
| | - Soraya Mebarki
- Geriatric Oncology Unit, European Georges-Pompidou Hospital, APHP Centre, Paris, France
| | - Mathilde Gisselbrecht
- Geriatric Oncology Unit, European Georges-Pompidou Hospital, APHP Centre, Paris, France
| | - Elisabeth Ashton
- Department of Medical Oncology, European Georges-Pompidou Hospital, APHP. Centre, France; Paris University, Faculty of Medicine, Paris, France
| | - Henri Azais
- Department of Gynecologic and Breast Oncological Surgery, European Georges-Pompidou Hospital, APHP. Centre, France; Paris University, Faculty of Medicine, Paris, France
| | - Meriem Koual
- Department of Gynecologic and Breast Oncological Surgery, European Georges-Pompidou Hospital, APHP. Centre, France; Paris University, Faculty of Medicine, Paris, France
| | - Anne-Sophie Bats
- Department of Gynecologic and Breast Oncological Surgery, European Georges-Pompidou Hospital, APHP. Centre, France; Paris University, Faculty of Medicine, Paris, France
| | - Laure Fournier
- Université de Paris, AP-HP, Hôpital européen Georges Pompidou, Department of Radiology, PARCC UMRS 970, INSERM, Paris, France
| | - Marie-Aude Le Frère - Belda
- Department of Pathology, European Georges-Pompidou Hospital, APHP. Centre, France; Paris University, Faculty of Medicine, Paris, France
| | - Jacques Medioni
- Department of Medical Oncology, European Georges-Pompidou Hospital, APHP. Centre, France; Paris University, Faculty of Medicine, Paris, France
| | - Elena Paillaud
- Geriatric Oncology Unit, European Georges-Pompidou Hospital, APHP Centre, France, Paris University, Faculty of Medicine, Paris, France
| | - Stephane Oudard
- Department of Medical Oncology, European Georges-Pompidou Hospital, APHP. Centre, France; Paris University, Faculty of Medicine, Paris, France
| | - Nicolas Delanoy
- Department of Medical Oncology, European Georges-Pompidou Hospital, APHP. Centre, France; Paris University, Faculty of Medicine, Paris, France
| |
Collapse
|
26
|
Duron L, Heraud A, Charbonneau F, Zmuda M, Savatovsky J, Fournier L, Lecler A. A Magnetic Resonance Imaging Radiomics Signature to Distinguish Benign From Malignant Orbital Lesions. Invest Radiol 2021; 56:173-180. [PMID: 32932375 DOI: 10.1097/rli.0000000000000722] [Citation(s) in RCA: 18] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
OBJECTIVES Distinguishing benign from malignant orbital lesions remains challenging both clinically and with imaging, leading to risky biopsies. The objective was to differentiate benign from malignant orbital lesions using radiomics on 3 T magnetic resonance imaging (MRI) examinations. MATERIALS AND METHODS This institutional review board-approved prospective single-center study enrolled consecutive patients presenting with an orbital lesion undergoing a 3 T MRI prior to surgery from December 2015 to July 2019. Radiomics features were extracted from 6 MRI sequences (T1-weighted images [WIs], DIXON-T2-WI, diffusion-WI, postcontrast DIXON-T1-WI) using the Pyradiomics software. Features were selected based on their intraobserver and interobserver reproducibility, nonredundancy, and with a sequential step forward feature selection method. Selected features were used to train and optimize a Random Forest algorithm on the training set (75%) with 5-fold cross-validation. Performance metrics were computed on a held-out test set (25%) with bootstrap 95% confidence intervals (95% CIs). Five residents, 4 general radiologists, and 3 expert neuroradiologists were evaluated on their ability to visually distinguish benign from malignant lesions on the test set. Performance comparisons between reader groups and the model were performed using McNemar test. The impact of clinical and categorizable imaging data on algorithm performance was also assessed. RESULTS A total of 200 patients (116 [58%] women and 84 [42%] men; mean age, 53.0 ± 17.9 years) with 126 of 200 (63%) benign and 74 of 200 (37%) malignant orbital lesions were included in the study. A total of 606 radiomics features were extracted. The best performing model on the training set was composed of 8 features including apparent diffusion coefficient mean value, maximum diameter on T1-WIs, and texture features. Area under the receiver operating characteristic curve, accuracy, sensitivity, and specificity on the test set were respectively 0.869 (95% CI, 0.834-0.898), 0.840 (95% CI, 0.806-0.874), 0.684 (95% CI, 0.615-0.751), and 0.935 (95% CI, 0.905-0.961). The radiomics model outperformed all reader groups, including expert neuroradiologists (P < 0.01). Adding clinical and categorizable imaging data did not significantly impact the algorithm performance (P = 0.49). CONCLUSIONS An MRI radiomics signature is helpful in differentiating benign from malignant orbital lesions and may outperform expert radiologists.
Collapse
Affiliation(s)
| | | | | | - Mathieu Zmuda
- Department of Orbitopalpebral Surgery, Fondation Adolphe de Rothschild Hospital
| | | | | | | |
Collapse
|
27
|
Seidler S, Koual M, Achen G, Bentivegna E, Fournier L, Delanoy N, Nguyen-Xuan HT, Bats AS, Azaïs H. Clinical Impact of Lymphadenectomy after Neoadjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer: A Review of Available Data. J Clin Med 2021; 10:jcm10020334. [PMID: 33477449 PMCID: PMC7830759 DOI: 10.3390/jcm10020334] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2020] [Revised: 01/09/2021] [Accepted: 01/13/2021] [Indexed: 12/02/2022] Open
Abstract
Recent robust data allow for omitting lymph node dissection for patients with advanced epithelial ovarian cancer (EOC) and without any suspicion of lymph node metastases, without compromising recurrence-free survival (RFS), nor overall survival (OS), in the setting of primary surgical treatment. Evidence supporting the same postulate for patients undergoing complete cytoreductive surgery after neoadjuvant chemotherapy (NACT) is lacking. Throughout a systematic literature review, the aim of our study was to evaluate the impact of lymph node dissection in patients undergoing surgery for advanced-stage EOC after NACT. A total of 1094 patients, included in six retrospective series, underwent either systematic, selective or no lymph node dissection. Only one study reveals a positive effect of lymphadenectomy on OS, and two on RFS. The four remaining series fail to demonstrate any beneficial effect on survival, neither for RFS nor OS. All of them highlight the higher peri- and post-operative complication rate associated with systematic lymph node dissection. Despite heterogeneity in the design of the studies included, there seems to be a trend showing no improvement on OS for systematic lymph node dissection in node negative patients. A well-conducted prospective trial is mandatory to evaluate this matter.
Collapse
Affiliation(s)
- Stephanie Seidler
- AP-HP.CUP, Service de Chirurgie Cancérologique Gynécologique et du Sein, Hôpital Européen Georges-Pompidou, 75015 Paris, France; (S.S.); (M.K.); (G.A.); (E.B.); (H.-T.N.-X.); (A.-S.B.)
- Swiss Medical Network, Clinique de Genolier, 1272 Genolier, Switzerland
| | - Meriem Koual
- AP-HP.CUP, Service de Chirurgie Cancérologique Gynécologique et du Sein, Hôpital Européen Georges-Pompidou, 75015 Paris, France; (S.S.); (M.K.); (G.A.); (E.B.); (H.-T.N.-X.); (A.-S.B.)
- Faculté de Médecine Paris-Descartes, Université de Paris, 75006 Paris, France;
- INSERM UMR-S 1124, Université de Paris, Centre Universitaire des Saints Pères, 75006 Paris, France
| | - Guillaume Achen
- AP-HP.CUP, Service de Chirurgie Cancérologique Gynécologique et du Sein, Hôpital Européen Georges-Pompidou, 75015 Paris, France; (S.S.); (M.K.); (G.A.); (E.B.); (H.-T.N.-X.); (A.-S.B.)
- Faculté de Médecine Paris-Descartes, Université de Paris, 75006 Paris, France;
| | - Enrica Bentivegna
- AP-HP.CUP, Service de Chirurgie Cancérologique Gynécologique et du Sein, Hôpital Européen Georges-Pompidou, 75015 Paris, France; (S.S.); (M.K.); (G.A.); (E.B.); (H.-T.N.-X.); (A.-S.B.)
| | - Laure Fournier
- Faculté de Médecine Paris-Descartes, Université de Paris, 75006 Paris, France;
- AP-HP.CUP, Service de Radiologie, Hôpital Européen Georges-Pompidou, 75015 Paris, France
| | - Nicolas Delanoy
- AP-HP.CUP, Service D’oncologie Médicale, Hôpital Européen Georges-Pompidou, 75015 Paris, France;
| | - Huyên-Thu Nguyen-Xuan
- AP-HP.CUP, Service de Chirurgie Cancérologique Gynécologique et du Sein, Hôpital Européen Georges-Pompidou, 75015 Paris, France; (S.S.); (M.K.); (G.A.); (E.B.); (H.-T.N.-X.); (A.-S.B.)
| | - Anne-Sophie Bats
- AP-HP.CUP, Service de Chirurgie Cancérologique Gynécologique et du Sein, Hôpital Européen Georges-Pompidou, 75015 Paris, France; (S.S.); (M.K.); (G.A.); (E.B.); (H.-T.N.-X.); (A.-S.B.)
- Faculté de Médecine Paris-Descartes, Université de Paris, 75006 Paris, France;
- Centre de Recherche des Cordeliers, INSERM UMR-S 1138, 75006 Paris, France
| | - Henri Azaïs
- AP-HP.CUP, Service de Chirurgie Cancérologique Gynécologique et du Sein, Hôpital Européen Georges-Pompidou, 75015 Paris, France; (S.S.); (M.K.); (G.A.); (E.B.); (H.-T.N.-X.); (A.-S.B.)
- Centre de Recherche des Cordeliers, INSERM UMR-S 1138, 75006 Paris, France
- Correspondence:
| |
Collapse
|
28
|
Alvarez JB, Bibault JE, Burgun A, Cai J, Cao Z, Chang K, Chen JH, Chen WC, Cho M, Cho PJ, Cornish TC, Costa A, Dekker A, Drukker K, Dunn J, Eminaga O, Erickson BJ, Fournier L, Gambhir SS, Gennatas ED, Giger ML, Halilaj I, Harrison AP, He B, Hong JC, Jin D, Jin MC, Jochems A, Kalpathy-Cramer J, Kapp DS, Karimzadeh M, Karnes W, Lambin P, Langlotz CP, Lee J, Li H, Liao JC, Lin AL, Lin RY, Liu Y, Lu L, Magnus D, McIntosh C, Miao S, Min JK, Neill DB, Oermann EK, Ouyang D, Peng L, Phene S, Poirot MG, Quon JL, Ranti D, Rao A, Raskar R, Rombaoa C, Rubin DL, Samarasena J, Seekins J, Seetharam K, Shearer E, Sibley A, Singh K, Singh P, Sordo M, Suraweera D, Valliani AAA, van Wijk Y, Vepakomma P, Wang B, Wang G, Wang N, Wang Y, Warner E, Welch M, Wong K, Wu Z, Xing F, Xing L, Yan K, Yan P, Yang L, Yeom KW, Zachariah R, Zeng D, Zhang L, Zhang L, Zhang X, Zhou L, Zou J. List of contributors. Artif Intell Med 2021. [DOI: 10.1016/b978-0-12-821259-2.00035-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
29
|
Planquette B, Le Berre A, Khider L, Yannoutsos A, Gendron N, de Torcy M, Mohamedi N, Jouveshomme S, Smadja DM, Lazareth I, Goudot G, Fournier L, Bruel C, Diehl JL, Mourad JJ, Meyer G, Priollet P, Messas E, Sanchez O, Beaussier H, Mirault T, Zins M, Chatelier G, Emmerich J. Prevalence and characteristics of pulmonary embolism in 1042 COVID-19 patients with respiratory symptoms: A nested case-control study. Thromb Res 2021; 197:94-99. [PMID: 33190025 PMCID: PMC7648521 DOI: 10.1016/j.thromres.2020.11.001] [Citation(s) in RCA: 37] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2020] [Revised: 10/12/2020] [Accepted: 11/03/2020] [Indexed: 01/08/2023]
Abstract
INTRODUCTION Coronavirus disease 2019 (COVID-19) has been associated with cardiovascular complications and coagulation disorders. Previous studies reported pulmonary embolism (PE) in severe COVID-19 patients. Aim of the study was to estimate the prevalence of symptomatic PE in COVID-19 patients and to identify the clinical, radiological or biological characteristics associated with PE. PATIENTS/METHODS We conducted a retrospective nested case-control study in 2 French hospitals. Controls were matched in a 1:2 ratio on the basis of age, sex and center. PE patients with COVID-19 were compared to patients in whom PE was ruled out (CTPA controls) and in whom PE has not been investigated (CT controls). RESULTS PE was suspected in 269 patients among 1042 COVID-19 patients, and confirmed in 59 patients (5.6%). Half of PE was diagnosed at COVID-19 diagnosis. PE patients did not differ from CT and CTPA controls for thrombosis risk factors. PE patients more often required invasive ventilation compared to CTPA controls (odds ratio (OR) 2.79; 95% confidence interval (CI) 1.33-5.84) and to CT controls (OR 8.07; 95% CI 2.70-23.82). PE patients exhibited more extensive parenchymal lesions (>50%) than CT controls (OR 3.90; 95% CI 1.54-9.94). D-dimer levels were 5.1 (95% CI 1.90-13.76) times higher in PE patients than CTPA controls. CONCLUSIONS Our results suggest a PE prevalence in COVID-19 patients close to 5% in the whole population and to 20% of the clinically suspected population. PE seems to be associated with more extensive lung damage and to require more frequently invasive ventilation.
Collapse
Affiliation(s)
- Benjamin Planquette
- Université de Paris, France; Innovative Therapies in Haemostasis, INSERM, F-75006 Paris, France; Biosurgical research lab (Carpentier Foundation), F-75015 Paris, France; Department of Respiratory Medicine, France; Assistance publique hôpitaux de Paris AH-HP, Hôpital européen Georges-Pompidou, F-75015 Paris, France.
| | - Alice Le Berre
- Department of Radiology, France; Groupe Hospitalier Paris Saint-Joseph, F-75014 Paris, France
| | - Lina Khider
- Université de Paris, France; Biosurgical research lab (Carpentier Foundation), F-75015 Paris, France; Assistance publique hôpitaux de Paris AH-HP, Hôpital européen Georges-Pompidou, F-75015 Paris, France; Physics for Medicine Paris, INSERM U1273, ESPCI Paris, CNRS FRE 2031, F-75011 Paris, France; Department of Vascular Medicine, France
| | - Alexandra Yannoutsos
- Groupe Hospitalier Paris Saint-Joseph, F-75014 Paris, France; Department of Vascular Medicine, France; INSERM CRESS UMR 1153, F-75005 Paris, France
| | - Nicolas Gendron
- Université de Paris, France; Innovative Therapies in Haemostasis, INSERM, F-75006 Paris, France; Biosurgical research lab (Carpentier Foundation), F-75015 Paris, France; Assistance publique hôpitaux de Paris AH-HP, Hôpital européen Georges-Pompidou, F-75015 Paris, France; Department of Haematology, France
| | - Marie de Torcy
- Department of Respiratory Medicine, France; Groupe Hospitalier Paris Saint-Joseph, F-75014 Paris, France
| | - Nassim Mohamedi
- Assistance publique hôpitaux de Paris AH-HP, Hôpital européen Georges-Pompidou, F-75015 Paris, France; Department of Vascular Medicine, France
| | - Stéphane Jouveshomme
- Department of Respiratory Medicine, France; Groupe Hospitalier Paris Saint-Joseph, F-75014 Paris, France
| | - David M Smadja
- Université de Paris, France; Innovative Therapies in Haemostasis, INSERM, F-75006 Paris, France; Biosurgical research lab (Carpentier Foundation), F-75015 Paris, France; Assistance publique hôpitaux de Paris AH-HP, Hôpital européen Georges-Pompidou, F-75015 Paris, France; Department of Haematology, France; F-CRIN INNOVTE, Saint-Étienne, France
| | - Isabelle Lazareth
- Groupe Hospitalier Paris Saint-Joseph, F-75014 Paris, France; Department of Vascular Medicine, France
| | - Guillaume Goudot
- Université de Paris, France; Biosurgical research lab (Carpentier Foundation), F-75015 Paris, France; Assistance publique hôpitaux de Paris AH-HP, Hôpital européen Georges-Pompidou, F-75015 Paris, France; Physics for Medicine Paris, INSERM U1273, ESPCI Paris, CNRS FRE 2031, F-75011 Paris, France; Department of Vascular Medicine, France
| | - Laure Fournier
- Université de Paris, France; Assistance publique hôpitaux de Paris AH-HP, Hôpital européen Georges-Pompidou, F-75015 Paris, France; Department of Radiology, France; Paris research cardiovascular center PARCC INSERM UMR-S 970, F-75015 Paris, France
| | - Cédric Bruel
- Groupe Hospitalier Paris Saint-Joseph, F-75014 Paris, France; Intensive Care Unit, France
| | - Jean Luc Diehl
- Université de Paris, France; Innovative Therapies in Haemostasis, INSERM, F-75006 Paris, France; Biosurgical research lab (Carpentier Foundation), F-75015 Paris, France; Assistance publique hôpitaux de Paris AH-HP, Hôpital européen Georges-Pompidou, F-75015 Paris, France; Intensive Care Unit, France
| | - Jean-Jacques Mourad
- Université de Paris, France; Groupe Hospitalier Paris Saint-Joseph, F-75014 Paris, France; Department of Internal Medicine, France
| | - Guy Meyer
- Université de Paris, France; Department of Respiratory Medicine, France; Assistance publique hôpitaux de Paris AH-HP, Hôpital européen Georges-Pompidou, F-75015 Paris, France; F-CRIN INNOVTE, Saint-Étienne, France; Paris research cardiovascular center PARCC INSERM UMR-S 970, F-75015 Paris, France; INSERM CIC 14-18, F-75015 Paris, France
| | - Pascal Priollet
- Groupe Hospitalier Paris Saint-Joseph, F-75014 Paris, France; Department of Vascular Medicine, France
| | - Emmanuel Messas
- Université de Paris, France; Assistance publique hôpitaux de Paris AH-HP, Hôpital européen Georges-Pompidou, F-75015 Paris, France; Physics for Medicine Paris, INSERM U1273, ESPCI Paris, CNRS FRE 2031, F-75011 Paris, France; Department of Vascular Medicine, France; Paris research cardiovascular center PARCC INSERM UMR-S 970, F-75015 Paris, France
| | - Olivier Sanchez
- Université de Paris, France; Innovative Therapies in Haemostasis, INSERM, F-75006 Paris, France; Biosurgical research lab (Carpentier Foundation), F-75015 Paris, France; Department of Respiratory Medicine, France; Assistance publique hôpitaux de Paris AH-HP, Hôpital européen Georges-Pompidou, F-75015 Paris, France; F-CRIN INNOVTE, Saint-Étienne, France
| | - Hélène Beaussier
- Groupe Hospitalier Paris Saint-Joseph, F-75014 Paris, France; Department of Clinical Investigation, France
| | - Tristan Mirault
- Université de Paris, France; Assistance publique hôpitaux de Paris AH-HP, Hôpital européen Georges-Pompidou, F-75015 Paris, France; Department of Vascular Medicine, France; Paris research cardiovascular center PARCC INSERM UMR-S 970, F-75015 Paris, France
| | - Marc Zins
- Department of Radiology, France; Groupe Hospitalier Paris Saint-Joseph, F-75014 Paris, France
| | - Gilles Chatelier
- Université de Paris, France; Assistance publique hôpitaux de Paris AH-HP, Hôpital européen Georges-Pompidou, F-75015 Paris, France; INSERM CIC 14-18, F-75015 Paris, France; Department of statistics, bioinformatics and public health, France
| | - Joseph Emmerich
- Université de Paris, France; Groupe Hospitalier Paris Saint-Joseph, F-75014 Paris, France; Department of Vascular Medicine, France; INSERM CRESS UMR 1153, F-75005 Paris, France
| |
Collapse
|
30
|
Jacques T, Fournier L, Zins M, Adamsbaum C, Chaumoitre K, Feydy A, Millet I, Montaudon M, Beregi JP, Bartoli JM, Cart P, Masson JP, Meder JF, Boyer L, Cotten A. Proposals for the use of artificial intelligence in emergency radiology. Diagn Interv Imaging 2020; 102:63-68. [PMID: 33279461 DOI: 10.1016/j.diii.2020.11.003] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2020] [Accepted: 11/13/2020] [Indexed: 12/30/2022]
Affiliation(s)
- Thibaut Jacques
- Department of Musculoskeletal Imaging, Lille University Hospital, 59000 Lille, France; Lille University School of Medicine, 59000 Lille, France.
| | - Laure Fournier
- Inserm, PARCC, 75015 Paris, France; Université de Paris, 75006 Paris, France; Radiology Department, Hôpital Européen Georges Pompidou, AP-HP, 75015 Paris, France; DRIM France IA, 75013 Paris, France; Collège des Enseignants en Radiologie de France (CERF), 75013 Paris, France
| | - Marc Zins
- DRIM France IA, 75013 Paris, France; Department of Medical Imaging, Saint-Joseph Hospital, 75014 Paris, France
| | - Catherine Adamsbaum
- Faculty of Medicine, Paris-Saclay University, 94270 Le-Kremlin-Bicêtre, France; Pediatric Radiology Department, Bicêtre Hospital, AP-HP, 94270 Le-Kremlin-Bicêtre, France
| | - Kathia Chaumoitre
- Imaging Department, Hôpital Nord, APHM, 13015 Marseille, France; Aix-Marseille University, 13007 Marseille, France
| | - Antoine Feydy
- Department of Radiology B, Cochin Hospital, AP-HP, 75014 Paris, France; Université de Paris, 75006 Paris, France
| | - Ingrid Millet
- Department of Medical Imaging, Lapeyronie University Hospital, 34295 Montpellier, France; Inserm, UMR, Institut Desbrest d'Épidémiologie et de Santé publique, University of Montpellier, 34000 Montpellier, France
| | - Michel Montaudon
- Collège des Enseignants en Radiologie de France (CERF), 75013 Paris, France; Department of Cardiovascular Imaging, Hôpital Cardiologique du Haut-Lévêque, CHU de Bordeaux, 33600 Pessac, France; Inserm U1045, IHU LIRYC, Université de Bordeaux, 33600 Pessac, France
| | - Jean-Paul Beregi
- DRIM France IA, 75013 Paris, France; Collège des Enseignants en Radiologie de France (CERF), 75013 Paris, France; Medical Imaging Group Nîmes, Nîmes University Hospital, 34000 Nîmes, France
| | - Jean-Michel Bartoli
- DRIM France IA, 75013 Paris, France; Collège des Enseignants en Radiologie de France (CERF), 75013 Paris, France; Radiology, La Timone Hospital, 13000 Marseille, France
| | - Philippe Cart
- Groupement Hospitalier Intercommunal Nord Ardennes, 08000 Charleville-Mézières, France; Syndicat des Radiologues Hospitaliers, 75004 Paris, France
| | - Jean-Philippe Masson
- DRIM France IA, 75013 Paris, France; Fédération Nationale des Médecins Radiologues, 75007 Paris, France
| | - Jean-François Meder
- Université de Paris, 75006 Paris, France; Department of Neuroradiology, Sainte-Anne Hospital, 75014 Paris, France; Inserm UMR 894, Faculty of Medicine, Pyschiatry and Neurosciences Centers, Paris Descartes University, Sorbonne Paris Cité, 75014 Paris, France; Société Française de Radiologie, 75013 Paris, France
| | - Louis Boyer
- Department of Radiology, Hôpital Montpied, CHU de Clermont-Ferrand, 63000 Clermont-Ferrand, France; TGI, Institut Pascal UMR 6602 UCA/CNRS/SIGMA Clermont, 63000 Clermont-Ferrand, France; Conseil National Professionnel de Radiologie (G4), 75013 Paris, France
| | - Anne Cotten
- Department of Musculoskeletal Imaging, Lille University Hospital, 59000 Lille, France; Lille University School of Medicine, 59000 Lille, France; Collège des Enseignants en Radiologie de France (CERF), 75013 Paris, France; Société Française de Radiologie, 75013 Paris, France
| |
Collapse
|
31
|
Lassau N, Bousaid I, Chouzenoux E, Lamarque J, Charmettant B, Azoulay M, Cotton F, Khalil A, Lucidarme O, Pigneur F, Benaceur Y, Sadate A, Lederlin M, Laurent F, Chassagnon G, Ernst O, Ferreti G, Diascorn Y, Brillet P, Creze M, Cassagnes L, Caramella C, Loubet A, Dallongeville A, Abassebay N, Ohana M, Banaste N, Cadi M, Behr J, Boussel L, Fournier L, Zins M, Beregi J, Luciani A, Cotten A, Meder J. Three artificial intelligence data challenges based on CT and MRI. Diagn Interv Imaging 2020; 101:783-788. [DOI: 10.1016/j.diii.2020.03.006] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2020] [Accepted: 03/12/2020] [Indexed: 02/07/2023]
|
32
|
Florin M, Pinar U, Chavigny E, Bouaboula M, Jarboui L, Coulibaly A, Lemogne C, Fournier L. Socio-economic and psychological impact of the COVID-19 outbreak on private practice and public hospital radiologists. Eur J Radiol 2020; 132:109285. [PMID: 32957001 PMCID: PMC7491419 DOI: 10.1016/j.ejrad.2020.109285] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2020] [Revised: 08/25/2020] [Accepted: 09/09/2020] [Indexed: 12/11/2022]
Abstract
During the COVID-19 outbreak, many radiologists expressed anxiety, depression and insomnia symptoms. Working in public hospital was a major protective factor for mental issues. Restricted access to education, past medical history and exposition to COVID-19 were common risks factor of anxiety or depression.
Purpose The COVID-19 pandemic has led to an urgent reorganisation of the healthcare system to prevent hospitals from overflowing and the virus from spreading. Our objective was to evaluate the socioeconomic and psychological impact of the COVID-19 outbreak on radiologists. Material and methods French radiologists were invited to answer an online survey during the pandemic through mailing lists. The questionnaire was accessible for nine days. It covered socio-demographic information, exposure to COVID-19 at work and impact on work organisation, and included the Insomnia Severity Index and Hospital Anxiety and Depression Scale. Outcomes were moderate to severe insomnia, definite symptoms of depression or anxiety. Risk and protective factors were identified through multivariate binary logistic regression. Results 1515 radiologists answered the survey. Overall, 674 (44.5 %) worked in a highCOVID-19 density area, 671 (44.3 %) were women, and 809 (53.4 %) worked in private practice. Among responders, 186 (12.3 %) expressed insomnia, 222 (14.6 %) anxiety, and 189 (12.5 %) depression symptoms. Lack of protective equipment, increased teleradiology activity and negative impact on education were risk factors for insomnia (respectively OR [95 %CI]:1.7[1.1−2.7], 1.5[1.1−2.2], and 2.5[1.8−3.6]). Female gender, respiratory history, working in COVID-19 high density area, increase of COVID-19 related activity, and impacted education were risk factors for anxiety (OR[95 %CI]:1.7[1.2−2.3], 2[1.1−3.4], 1.5[1.1−2], 1.2[1−1.4], and 2.1[1.5−3]). Conversely, working in a public hospital was a protective factor against insomnia, anxiety, and depression (OR[95 %CI]:0.4[0.2−0.7], 0.6[0.4−0.9], and 0.5[0.3−0.8]). Conclusions During COVID-19 pandemic, many radiologists expressed depression, anxiety and insomnia symptoms. Working in a public hospital was a protective factor against every psychological symptom. Socio-economic impact was also major especially in private practice.
Collapse
Affiliation(s)
- Marie Florin
- Université de Paris, AP-HP, Hôpital Européen Georges Pompidou, Radiology Department, 20 rue Leblanc, F-75015, Paris, France.
| | - Ugo Pinar
- Sorbonne université, APHP, Hôpital la Pitié-Salpêtrière, Urology and Renal Transplantation Department, F-75013, Paris, France
| | | | - Mehdi Bouaboula
- Université de Paris, AP-HP, Hôpital Européen Georges Pompidou, Radiology Department, 20 rue Leblanc, F-75015, Paris, France
| | - Lamia Jarboui
- Centre cardiologique du nord, Radiology Department, 93200, Saint-Denis, France
| | - Adamfa Coulibaly
- Centre hospitalier de Poitiers, Radiology Department, 86000, Poitiers, France
| | - Cédric Lemogne
- Université de Paris, INSERM, Institut de Psychiatrie et Neurosciences de Paris (IPNP), UMR_S1266, 102-108 rue de la Santé, F-75014, Paris, France; AP-HP Centre-Université de Paris, Hôpital européen Georges Pompidou, service de psychiatrie et d'addictologie de l'adulte et du sujet agé, F-75015, Paris, France
| | - Laure Fournier
- Université de Paris, AP-HP, Hôpital Européen Georges Pompidou, Radiology Department, 20 rue Leblanc, F-75015, Paris, France
| |
Collapse
|
33
|
Deroose CM, Lecouvet FE, Collette L, Oprea-Lager DE, Kunz WG, Bidaut L, Verhoeff JJC, Caramella C, Lopci E, Tombal B, de Geus-Oei LF, Fournier L, Smits M, deSouza NM. Impact of the COVID-19 crisis on imaging in oncological trials. Eur J Nucl Med Mol Imaging 2020; 47:2054-2058. [PMID: 32533240 PMCID: PMC7289713 DOI: 10.1007/s00259-020-04910-y] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Affiliation(s)
- Christophe M Deroose
- European Organisation for Research and Treatment of Cancer (EORTC) Imaging Group, Brussels, Belgium.
- Nuclear Medicine, University Hospitals Leuven, Leuven, Belgium.
- Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Leuven, Belgium.
| | - Frédéric E Lecouvet
- European Organisation for Research and Treatment of Cancer (EORTC) Imaging Group, Brussels, Belgium
- Department of Radiology, Institut de Recherche Expérimentale et Clinique, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain (UCLouvain), Brussels, Belgium
| | - Laurence Collette
- European Organisation for Research and Treatment of Cancer (EORTC) Headquarters, Brussels, Belgium
| | - Daniela E Oprea-Lager
- European Organisation for Research and Treatment of Cancer (EORTC) Imaging Group, Brussels, Belgium
- Department of Radiology & Nuclear Medicine, Amsterdam University Medical Centers (VU University), Amsterdam, The Netherlands
| | - Wolfgang G Kunz
- European Organisation for Research and Treatment of Cancer (EORTC) Imaging Group, Brussels, Belgium
- Department of Radiology, University Hospital, LMU Munich, Munich, Germany
| | - Luc Bidaut
- European Organisation for Research and Treatment of Cancer (EORTC) Imaging Group, Brussels, Belgium
- College of Science, University of Lincoln, Lincoln, UK
| | - Joost J C Verhoeff
- European Organisation for Research and Treatment of Cancer (EORTC) Imaging Group, Brussels, Belgium
- Department of Radiation Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands
| | - Caroline Caramella
- European Organisation for Research and Treatment of Cancer (EORTC) Imaging Group, Brussels, Belgium
- Radiology Department, Hôpital Marie Lannelongue, Institut d'Oncologie Thoracique, Université Paris-Saclay, Le Plessis-Robinson, France
| | - Egesta Lopci
- European Organisation for Research and Treatment of Cancer (EORTC) Imaging Group, Brussels, Belgium
- Nuclear Medicine, Humanitas Clinical and Research Hospital - IRCCS, Rozzano, Milan, Italy
| | - Bertrand Tombal
- Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium
| | - Lioe-Fee de Geus-Oei
- European Organisation for Research and Treatment of Cancer (EORTC) Imaging Group, Brussels, Belgium
- Department of Radiology, Section of Nuclear Medicine, Leiden University Medical Center, Leiden, The Netherlands
| | - Laure Fournier
- European Organisation for Research and Treatment of Cancer (EORTC) Imaging Group, Brussels, Belgium
- Department of Radiology, AP-HP, Hôpital Européen Georges Pompidou, Université de Paris, Paris, France
| | - Marion Smits
- European Organisation for Research and Treatment of Cancer (EORTC) Imaging Group, Brussels, Belgium
- Department of Radiology & Nuclear Medicine, Erasmus MC - University Medical Centre Rotterdam, Rotterdam, The Netherlands
| | - Nandita M deSouza
- European Organisation for Research and Treatment of Cancer (EORTC) Imaging Group, Brussels, Belgium
- Cancer Research UK Imaging Centre, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust-Sutton, Sutton, UK
| |
Collapse
|
34
|
Fournier L, Véra P, Giraud P. Avancées de l’imagerie anatomique et fonctionnelle au service de la radiothérapie. Cancer Radiother 2020; 24:357. [DOI: 10.1016/j.canrad.2020.06.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
35
|
Bompard F, Monnier H, Saab I, Tordjman M, Abdoul H, Fournier L, Sanchez O, Lorut C, Chassagnon G, Revel MP. Pulmonary embolism in patients with COVID-19 pneumonia. Eur Respir J 2020; 56:13993003.01365-2020. [PMID: 32398297 PMCID: PMC7236820 DOI: 10.1183/13993003.01365-2020] [Citation(s) in RCA: 252] [Impact Index Per Article: 63.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2020] [Accepted: 04/29/2020] [Indexed: 12/18/2022]
Abstract
Acute respiratory distress syndrome development in patients with coronavirus disease 2019 (COVID-19) pneumonia is associated with a high mortality rate and is the main cause of death in patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection [1]. Myocardial injury has also been reported to be significantly associated with fatal outcome, with a 37% mortality rate in patients without prior cardiovascular disease but elevated troponin levels [2]. A D-dimer level of >1 μg·mL−1 has been clearly identified as a risk factor for poor outcome in SARS-Cov-2 infection [3], with recent reports highlighting a high incidence of thrombotic events in intensive care unit (ICU) patients [4]. A normal D-dimer level allows the safe exclusion of pulmonary embolism (PE) in outpatients with a low or intermediate clinical probability of PE, but there is no recommendation to use D-dimer as a positive marker of thrombosis because of lack of specificity. This study reports an overall 24% (95% CI 17–32%) cumulative incidence of pulmonary embolism in patients with COVID-19 pneumonia, 50% (30–70%) in ICU and 18% (12–27%) in other patientshttps://bit.ly/35s7hjm
Collapse
Affiliation(s)
- Florian Bompard
- Dept of Radiology, Cochin Hospital, AP-HP Centre, Paris, France
| | - Hippolyte Monnier
- Dept of Radiology, Hôpital Européen Georges-Pompidou, AP-HP Centre, Paris, France
| | - Ines Saab
- Dept of Radiology, Cochin Hospital, AP-HP Centre, Paris, France.,Université de Paris, Descartes-Paris 5, Paris, France
| | | | - Hendy Abdoul
- Unité de Recherche Clinique Centre d'Investigation Clinique, Paris Descartes Necker/Cochin, Hôpital Tarnier, Paris, France
| | - Laure Fournier
- Dept of Radiology, Hôpital Européen Georges-Pompidou, AP-HP Centre, Paris, France.,Université de Paris, Descartes-Paris 5, Paris, France
| | - Olivier Sanchez
- Université de Paris, Descartes-Paris 5, Paris, France.,Dept of Pulmonology and Intensive Care, Hôpital Européen Georges-Pompidou, AP-HP Centre, Paris, France
| | - Christine Lorut
- Dept of Pulmonology, Cochin Hospital, AP-HP Centre, Paris, France
| | - Guillaume Chassagnon
- Dept of Radiology, Cochin Hospital, AP-HP Centre, Paris, France.,Université de Paris, Descartes-Paris 5, Paris, France
| | - Marie-Pierre Revel
- Dept of Radiology, Cochin Hospital, AP-HP Centre, Paris, France .,Université de Paris, Descartes-Paris 5, Paris, France
| |
Collapse
|
36
|
Simonaggio A, Elaidi R, Fournier L, Fabre E, Ferrari V, Borchiellini D, Thouvenin J, Barthelemy P, Thibault C, Tartour E, Oudard S, Vano YA. Variation in neutrophil to lymphocyte ratio (NLR) as predictor of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (mNSCLC) patients treated with nivolumab. Cancer Immunol Immunother 2020; 69:2513-2522. [PMID: 32561968 DOI: 10.1007/s00262-020-02637-1] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2020] [Accepted: 06/10/2020] [Indexed: 12/14/2022]
Abstract
BACKGROUND An elevated pre-treatment neutrophil to lymphocytes ratio (NLR) is associated with poor prognosis in various malignancies. Optimal cut-off is highly variable across studies and could not be determined individually for a patient to inform his prognosis. We hypothesize that NLR variations could be more useful than baseline NLR to predict progression-free survival (PFS) and overall survival (OS) in patients (pts) receiving anti-PD1 treatment. PATIENTS AND METHODS All pts with metastatic renal cell carcinoma (mRCC) and metastatic non-small cell lung cancer (mNSCLC) who received anti-PD1 nivolumab monotherapy in second-line setting or later were included in this French multicentric retrospective study. NLR values were prospectively collected prior to each nivolumab administration. Clinical characteristics were recorded. Associations between baseline NLR, NLR variations and survival outcomes were determined using Kaplan-Meier's method and multivariable Cox regression models. RESULTS 161 pts (86 mRCC and 75 mNSCLC) were included with a median follow-up of 18 months. On the whole cohort, any NLR increase at week 6 was significantly associated with worse outcomes compared to NLR decrease, with a median PFS of 11 months vs 3.7 months (p < 0.0001), and a median OS of 28.5 months vs. 18 months (p = 0.013), respectively. In multivariate analysis, NLR increase was significantly associated with worse PFS (HR 2.2; p = 6.10-5) and OS (HR 2.1; p = 0.005). Consistent results were observed in each cohort when analyzed separately. CONCLUSION Any NLR increase at week 6 was associated with worse PFS and OS outcomes. NLR variation is an inexpensive and dynamic marker easily obtained to monitor anti-PD1 efficacy.
Collapse
Affiliation(s)
- A Simonaggio
- Medical Oncology Department, Hôpital Européen Georges Pompidou, Paris, France
| | - R Elaidi
- Medical Oncology Department, Hôpital Européen Georges Pompidou, Paris, France
| | - L Fournier
- Department of Radiology, Hôpital Européen Georges Pompidou, Paris, France
| | - E Fabre
- Medical Thoracic Oncology Department, Hopital Européen Georges Pompidou, Paris, France
- U970, Université Paris Descartes Sorbonne Paris-Cité, 75006, Paris, France
| | - V Ferrari
- Department of Medical Oncology, Centre Antoine Lacassagne, Université Côte d'Azur, Nice, France
| | - D Borchiellini
- Department of Medical Oncology, Centre Antoine Lacassagne, Université Côte d'Azur, Nice, France
| | - J Thouvenin
- Department of Medical Oncology, University Hospital of Strasbourg, Strasbourg, France
| | - P Barthelemy
- Department of Medical Oncology, University Hospital of Strasbourg, Strasbourg, France
| | - C Thibault
- Medical Oncology Department, Hôpital Européen Georges Pompidou, Paris, France
| | - E Tartour
- Department of Immunology, Hôpital Européen Georges Pompidou, 75015, Paris, France
- U970, Université Paris Descartes Sorbonne Paris-Cité, 75006, Paris, France
| | - S Oudard
- Medical Oncology Department, Hôpital Européen Georges Pompidou, Paris, France
| | - Y A Vano
- Medical Oncology Department, Hôpital Européen Georges Pompidou, Paris, France.
- INSERM, UMR-S 1138, Centre de Recherche des Cordeliers, Team "Cancer, Immune Control and Escape", University Paris Descartes Sorbonne, 75006, Paris, France.
| |
Collapse
|
37
|
Hazard A, Bourrion B, Dechaine F, Fournier L, François M. Lack of evidence for allopurinol for the prevention of a first gout attack in asymptomatic hyperuricemia: a systematic review. Eur J Clin Pharmacol 2020; 76:897-899. [PMID: 32100073 DOI: 10.1007/s00228-020-02849-5] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2019] [Accepted: 02/14/2020] [Indexed: 11/25/2022]
Affiliation(s)
- A Hazard
- Département de médecine générale, UFR des sciences de la santé Simone Veil, Université Versailles-Saint-Quentin-en-Yvelines, Montigny le Bretonneux, France.
| | - B Bourrion
- Département de médecine générale, UFR des sciences de la santé Simone Veil, Université Versailles-Saint-Quentin-en-Yvelines, Montigny le Bretonneux, France
- INSERM, Centre de Recherche en Epidémiologie et Santé des Populations, UMR1018, Hôpital Paul Brousse, Université Paris Saclay, bat 15-16, 16 avenue Paul Vaillant Couturier, 94807, Villejuif CEDEX, France
| | - F Dechaine
- Département de médecine générale, UFR des sciences de la santé Simone Veil, Université Versailles-Saint-Quentin-en-Yvelines, Montigny le Bretonneux, France
| | - L Fournier
- INSERM, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), Sorbonne Université, F-75012, Paris, France
| | - M François
- Département de médecine générale, UFR des sciences de la santé Simone Veil, Université Versailles-Saint-Quentin-en-Yvelines, Montigny le Bretonneux, France
- INSERM, Centre de Recherche en Epidémiologie et Santé des Populations, UMR1018, Hôpital Paul Brousse, Université Paris Saclay, bat 15-16, 16 avenue Paul Vaillant Couturier, 94807, Villejuif CEDEX, France
| |
Collapse
|
38
|
Le Berre C, Sandborn WJ, Aridhi S, Devignes MD, Fournier L, Smaïl-Tabbone M, Danese S, Peyrin-Biroulet L. Application of Artificial Intelligence to Gastroenterology and Hepatology. Gastroenterology 2020; 158:76-94.e2. [PMID: 31593701 DOI: 10.1053/j.gastro.2019.08.058] [Citation(s) in RCA: 259] [Impact Index Per Article: 64.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/20/2018] [Revised: 08/22/2019] [Accepted: 08/24/2019] [Indexed: 02/07/2023]
Abstract
Since 2010, substantial progress has been made in artificial intelligence (AI) and its application to medicine. AI is explored in gastroenterology for endoscopic analysis of lesions, in detection of cancer, and to facilitate the analysis of inflammatory lesions or gastrointestinal bleeding during wireless capsule endoscopy. AI is also tested to assess liver fibrosis and to differentiate patients with pancreatic cancer from those with pancreatitis. AI might also be used to establish prognoses of patients or predict their response to treatments, based on multiple factors. We review the ways in which AI may help physicians make a diagnosis or establish a prognosis and discuss its limitations, knowing that further randomized controlled studies will be required before the approval of AI techniques by the health authorities.
Collapse
Affiliation(s)
- Catherine Le Berre
- Institut des Maladies de l'Appareil Digestif, Nantes University Hospital, France; Institut National de la Santé et de la Recherche Médicale U954 and Department of Gastroenterology, Nancy University Hospital, University of Lorraine, France
| | | | - Sabeur Aridhi
- University of Lorraine, Le Centre National de la Recherche Scientifique, Inria, Laboratoire Lorrain de Recherche en Informatique et ses Applications, Nancy, France
| | - Marie-Dominique Devignes
- University of Lorraine, Le Centre National de la Recherche Scientifique, Inria, Laboratoire Lorrain de Recherche en Informatique et ses Applications, Nancy, France
| | - Laure Fournier
- Université Paris-Descartes, Institut National de la Santé et de la Recherche Médicale, Unité Mixte De Recherché S970, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Malika Smaïl-Tabbone
- University of Lorraine, Le Centre National de la Recherche Scientifique, Inria, Laboratoire Lorrain de Recherche en Informatique et ses Applications, Nancy, France
| | - Silvio Danese
- Inflammatory Bowel Disease Center and Department of Biomedical Sciences, Humanitas Clinical and Research Center, Humanitas University, Milan, Italy
| | - Laurent Peyrin-Biroulet
- Institut National de la Santé et de la Recherche Médicale U954 and Department of Gastroenterology, Nancy University Hospital, University of Lorraine, France.
| |
Collapse
|
39
|
Bourrion B, Hazard A, Baltazard H, Sebbag P, Fournier L, François M. [Naftidrofuryl in arterial obstructive disease: A systematic revue of the literature]. Rev Med Interne 2019; 41:89-97. [PMID: 31669163 DOI: 10.1016/j.revmed.2019.10.001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2019] [Revised: 08/06/2019] [Accepted: 10/01/2019] [Indexed: 11/16/2022]
Abstract
INTRODUCTION Arterial obstructive disease is a disease affecting 11 % of the general population. This prevalence is constantly increasing. Nafronyl is still prescribed despite a decreasing reimbursement rate since 2005. The objective of this study was to summarize data from the scientific literature on the efficacy and safety of nafronyl used for the treatment of peripheral arterial obstructive disease. METHOD A systematic review was made on EMBASE, MEDLINE and the Cochrane Library. Randomized controlled trials, systematic reviews and meta-analyses comparing naftidrofuryl with placebo were included. The main outcome was an improvement in the maximum walking distance or pain free walking distance. The quality of the reviews was analysed using a standardised reading grid. Only the best study was retained. RESULTS Among 193articles, one meta-analyses were selected. Naftidrofuryl improved the initial pain free walking distance by 60 % at six months, without a demonstrated increase in the risk of adverse reactions. CONCLUSION The efficacy of naftidrofuryl over the maximum walking distance in peripheral arterial obstructive disease appears similar to physical exercise or simvastatin.
Collapse
Affiliation(s)
- B Bourrion
- Département de médecine générale, faculté des sciences de la santé Simone-Veille, université Versailles-Saint-Quentin-en-Yvelines, 78180, Montigny le Bretonneux, France; Université Paris Saclay, Inserm, centre de recherche en épidémiologie et santé des populations, UMR1018, hôpital Pau-Brousse, bat 15-16, 16, avenue Paul-Vaillant Couturier, 94807 Villejuif cedex, France.
| | - A Hazard
- Département de médecine générale, faculté des sciences de la santé Simone-Veille, université Versailles-Saint-Quentin-en-Yvelines, 78180, Montigny le Bretonneux, France
| | - H Baltazard
- Département de médecine générale, faculté des sciences de la santé Simone-Veille, université Versailles-Saint-Quentin-en-Yvelines, 78180, Montigny le Bretonneux, France
| | - P Sebbag
- Département de médecine générale, faculté des sciences de la santé Simone-Veille, université Versailles-Saint-Quentin-en-Yvelines, 78180, Montigny le Bretonneux, France
| | - L Fournier
- Sorbonne universités, UPMC université Paris 06, Inserm, institut Pierre-Louis d'épidémiologie et de santé publique (IPLESP UMRS 1136), 75013, Paris, France
| | - M François
- Département de médecine générale, faculté des sciences de la santé Simone-Veille, université Versailles-Saint-Quentin-en-Yvelines, 78180, Montigny le Bretonneux, France; Université Paris Saclay, Inserm, centre de recherche en épidémiologie et santé des populations, UMR1018, hôpital Pau-Brousse, bat 15-16, 16, avenue Paul-Vaillant Couturier, 94807 Villejuif cedex, France
| |
Collapse
|
40
|
Hankard A, Fournier L, Lobbedez T, Aouba A, Audemard-Verger A. [Encapsulant peritonitis]. Rev Med Interne 2019; 41:130-133. [PMID: 31635978 DOI: 10.1016/j.revmed.2019.09.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2019] [Revised: 08/21/2019] [Accepted: 09/26/2019] [Indexed: 11/24/2022]
Abstract
INTRODUCTION Encapsulating peritonitis is a rare but severe chronic fibrotic condition related to the development of a white fibrous membrane surrounding the digestive tract. Idiopathic forms have been described, however the disease is most often secondary to peritoneal dialysis or more rarely to surgery. Treatment is difficult and not codified. CASE REPORT We report here the observation of a 36-year-old patient whose diagnosis of encapsulating peritonitis was made after a long sub-occlusive history, eight years after a gastric ulcer perforation. DISCUSSION We discuss the possible etiologies and we present a focus on this rare and little-known entity.
Collapse
Affiliation(s)
- A Hankard
- Service de médecine interne et d'immunologie clinique, CHU de Caen, 14000 Caen, France
| | - L Fournier
- Service de radiologie, CHU de Caen, 14000 Caen, France
| | - T Lobbedez
- Service néphrologie, CHU de Caen, 14000 Caen, France
| | - A Aouba
- Service de médecine interne et d'immunologie clinique, CHU de Caen, 14000 Caen, France
| | - A Audemard-Verger
- Service de médecine interne et d'immunologie clinique, CHU de Caen, 14000 Caen, France.
| |
Collapse
|
41
|
Hans S, Simonaggio A, Hamidatou K, Fournier L, Thibault C, Elaidi RT, Oudard S, Vano Y. Nivolumab (N) treatment beyond progression in a real-world cohort of patients (pts) with metastatic renal cell carcinoma (mRCC). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz249.056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
42
|
deSouza NM, Achten E, Alberich-Bayarri A, Bamberg F, Boellaard R, Clément O, Fournier L, Gallagher F, Golay X, Heussel CP, Jackson EF, Manniesing R, Mayerhofer ME, Neri E, O'Connor J, Oguz KK, Persson A, Smits M, van Beek EJR, Zech CJ. Validated imaging biomarkers as decision-making tools in clinical trials and routine practice: current status and recommendations from the EIBALL* subcommittee of the European Society of Radiology (ESR). Insights Imaging 2019; 10:87. [PMID: 31468205 PMCID: PMC6715762 DOI: 10.1186/s13244-019-0764-0] [Citation(s) in RCA: 51] [Impact Index Per Article: 10.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2019] [Accepted: 06/28/2019] [Indexed: 12/12/2022] Open
Abstract
Observer-driven pattern recognition is the standard for interpretation of medical images. To achieve global parity in interpretation, semi-quantitative scoring systems have been developed based on observer assessments; these are widely used in scoring coronary artery disease, the arthritides and neurological conditions and for indicating the likelihood of malignancy. However, in an era of machine learning and artificial intelligence, it is increasingly desirable that we extract quantitative biomarkers from medical images that inform on disease detection, characterisation, monitoring and assessment of response to treatment. Quantitation has the potential to provide objective decision-support tools in the management pathway of patients. Despite this, the quantitative potential of imaging remains under-exploited because of variability of the measurement, lack of harmonised systems for data acquisition and analysis, and crucially, a paucity of evidence on how such quantitation potentially affects clinical decision-making and patient outcome. This article reviews the current evidence for the use of semi-quantitative and quantitative biomarkers in clinical settings at various stages of the disease pathway including diagnosis, staging and prognosis, as well as predicting and detecting treatment response. It critically appraises current practice and sets out recommendations for using imaging objectively to drive patient management decisions.
Collapse
Affiliation(s)
- Nandita M deSouza
- Cancer Research UK Imaging Centre, The Institute of Cancer Research and The Royal Marsden Hospital, Downs Road, Sutton, Surrey, SM2 5PT, UK.
| | | | | | - Fabian Bamberg
- Department of Radiology, University of Freiburg, Freiburg im Breisgau, Germany
| | | | | | | | | | | | - Claus Peter Heussel
- Universitätsklinik Heidelberg, Translational Lung Research Center (TLRC), German Center for Lung Research (DZL), University of Heidelberg, Im Neuenheimer Feld 156, 69120, Heidelberg, Germany
| | - Edward F Jackson
- University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
| | - Rashindra Manniesing
- Department of Radiology and Nuclear Medicine, Radboud University Medical Center, Geert Grooteplein 10, 6525, GA, Nijmegen, The Netherlands
| | | | - Emanuele Neri
- Department of Translational Research, University of Pisa, Pisa, Italy
| | - James O'Connor
- Division of Cancer Sciences, University of Manchester, Manchester, UK
| | | | | | - Marion Smits
- Department of Radiology and Nuclear Medicine (Ne-515), Erasmus MC, PO Box 2040, 3000, CA, Rotterdam, The Netherlands
| | - Edwin J R van Beek
- Edinburgh Imaging, Queen's Medical Research Institute, Edinburgh Bioquarter, 47 Little France Crescent, Edinburgh, UK
| | - Christoph J Zech
- University Hospital Basel, Radiology and Nuclear Medicine, University of Basel, Petersgraben 4, CH-4031, Basel, Switzerland
| |
Collapse
|
43
|
Sun S, Bonaffini PA, Nougaret S, Fournier L, Dohan A, Chong J, Smith J, Addley H, Reinhold C. How to differentiate uterine leiomyosarcoma from leiomyoma with imaging. Diagn Interv Imaging 2019; 100:619-634. [PMID: 31427216 DOI: 10.1016/j.diii.2019.07.007] [Citation(s) in RCA: 50] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2019] [Revised: 07/14/2019] [Accepted: 07/15/2019] [Indexed: 12/16/2022]
Abstract
Uterine leiomyomas, the most frequent benign myomatous tumors of the uterus, often cannot be distinguished from malignant uterine leiomyosarcomas using clinical criteria. Furthermore, imaging differentiation between both entities is frequently challenging due to their potential overlapping features. Because a suspected leiomyoma is often managed conservatively or with minimally invasive treatments, the misdiagnosis of leiomyosarcoma for a benign leiomyoma could potentially result in significant treatment delays, therefore increasing morbidity and mortality. In this review, we provide an overview of the differences between leiomyoma and leiomyosarcoma, mainly focusing on imaging characteristics, but also briefly touching upon their demographic, histopathological and clinical differences. The main indications and limitations of available cross-sectional imaging techniques are discussed, including ultrasound, computed tomography, magnetic resonance imaging (MRI) and positron emission tomography/computed tomography. A particular emphasis is placed on the review of specific MRI features that may allow distinction between leiomyomas and leiomyosarcomas according to the most recent evidence in the literature. The potential contribution of texture analysis is also discussed. In order to help guide-imaging diagnosis, we provide an MRI-based diagnostic algorithm which takes into account morphological and functional features, both individually and in combination, in an attempt to optimize radiologic differentiation of leiomyomas from leiomyosarcomas.
Collapse
Affiliation(s)
- S Sun
- Department of Radiology, McGill University Health Centre, 1001 Decarie boulevard, H4A 3J1 Montreal, QC, Canada.
| | - P A Bonaffini
- Department of Radiology, McGill University Health Centre, 1001 Decarie boulevard, H4A 3J1 Montreal, QC, Canada
| | - S Nougaret
- Inserm, U1194, Department of Radiology, Montpellier Cancer Institute, University of Montpellier, 34295 Montpellier, France
| | - L Fournier
- Université de Paris, Descartes-Paris 5, 75006 Paris, France; Department of Radiology, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, 75015 Paris, France
| | - A Dohan
- Université de Paris, Descartes-Paris 5, 75006 Paris, France; Department of Radiology A, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, 75014 Paris, France
| | - J Chong
- Department of Radiology, McGill University Health Centre, 1001 Decarie boulevard, H4A 3J1 Montreal, QC, Canada
| | - J Smith
- Department of Radiology, Cambridge University Hospitals, NHS Foundation Trust, CB2 0QQ Cambridge, United Kingdom
| | - H Addley
- Department of Radiology, Cambridge University Hospitals, NHS Foundation Trust, CB2 0QQ Cambridge, United Kingdom
| | - C Reinhold
- Department of Radiology, McGill University Health Centre, 1001 Decarie boulevard, H4A 3J1 Montreal, QC, Canada
| |
Collapse
|
44
|
Lavoue V, Huchon C, Akladios C, Alfonsi P, Bakrin N, Ballester M, Bendifallah S, Bolze P, Bonnet F, Bourgin C, Chabbert-Buffet N, Collinet P, Courbiere B, De la motte rouge T, Devouassoux-Shisheboran M, Falandry C, Ferron G, Fournier L, Gladieff L, Golfier F, Gouy S, Guyon F, Lambaudie E, Leary A, Lecuru F, Lefrere-Belda M, Leblanc E, Lemoine A, Narducci F, Ouldamer L, Pautier P, Planchamp F, Pouget N, Ray-Coquard I, Rousset-Jablonski C, Senechal-Davin C, Touboul C, Thomassin-Naggara I, Uzan C, You B, Daraï E. Management of epithelial cancer of the ovary, fallopian tube, primary peritoneum. Long text of the joint French clinical practice guidelines issued by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY, endorsed by INCa. (Part 2: systemic, intraperitoneal treatment, elderly patients, fertility preservation, follow-up). J Gynecol Obstet Hum Reprod 2019; 48:379-386. [DOI: 10.1016/j.jogoh.2019.03.018] [Citation(s) in RCA: 16] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2019] [Accepted: 03/19/2019] [Indexed: 10/27/2022]
|
45
|
Lecler A, Balvay D, Cuenod C, Marais L, Zmuda M, Sadik J, Galatoire O, Farah E, El Methni J, Zuber K, Bergès O, Savatovsky J, Fournier L. Quality‐based pharmacokinetic model selection on DCE‐MRI for characterizing orbital lesions. J Magn Reson Imaging 2019; 50:1514-1525. [DOI: 10.1002/jmri.26747] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2018] [Revised: 03/15/2019] [Accepted: 03/18/2019] [Indexed: 12/18/2022] Open
Affiliation(s)
- Augustin Lecler
- Department of NeuroradiologyFoundation Adolphe de Rothschild Hospital Paris France
- Université Paris Descartes Sorbonne Paris Cité, INSERM UMR‐S970Cardiovascular Research Center – PARCC Paris France
| | - Daniel Balvay
- Université Paris Descartes Sorbonne Paris Cité, INSERM UMR‐S970Cardiovascular Research Center – PARCC Paris France
| | - Charles‐André Cuenod
- Université Paris Descartes Sorbonne Paris Cité, INSERM UMR‐S970Cardiovascular Research Center – PARCC Paris France
- Radiology Department, Hôpital Européen Georges PompidouUniversité Paris Descartes Sorbonne Paris Cité, Assistance Publique‐Hôpitaux de Paris Paris France
| | - Louise Marais
- Université Paris Descartes Sorbonne Paris Cité, INSERM UMR‐S970Cardiovascular Research Center – PARCC Paris France
| | - Mathieu Zmuda
- Department of Orbitopalpebral SurgeryFoundation Adolphe de Rothschild Hospital Paris France
| | - Jean‐Claude Sadik
- Department of NeuroradiologyFoundation Adolphe de Rothschild Hospital Paris France
| | - Olivier Galatoire
- Department of Orbitopalpebral SurgeryFoundation Adolphe de Rothschild Hospital Paris France
| | - Edgar Farah
- Department of Orbitopalpebral SurgeryFoundation Adolphe de Rothschild Hospital Paris France
| | - Jonathan El Methni
- MAP5, UMR CNRS 8145Université Paris Descartes Sorbonne Paris Cité France
| | - Kevin Zuber
- Department of Clinical ResearchFoundation Adolphe de Rothschild Hospital Paris France
| | - Olivier Bergès
- Department of NeuroradiologyFoundation Adolphe de Rothschild Hospital Paris France
| | - Julien Savatovsky
- Department of NeuroradiologyFoundation Adolphe de Rothschild Hospital Paris France
| | - Laure Fournier
- Université Paris Descartes Sorbonne Paris Cité, INSERM UMR‐S970Cardiovascular Research Center – PARCC Paris France
- Radiology Department, Hôpital Européen Georges PompidouUniversité Paris Descartes Sorbonne Paris Cité, Assistance Publique‐Hôpitaux de Paris Paris France
| |
Collapse
|
46
|
Lassau N, Estienne T, de Vomecourt P, Azoulay M, Cagnol J, Garcia G, Majer M, Jehanno E, Renard-Penna R, Balleyguier C, Bidault F, Caramella C, Jacques T, Dubrulle F, Behr J, Poussange N, Bocquet J, Montagne S, Cornelis F, Faruch M, Bresson B, Brunelle S, Jalaguier-Coudray A, Amoretti N, Blum A, Paisant A, Herreros V, Rouviere O, Si-Mohamed S, Di Marco L, Hauger O, Garetier M, Pigneur F, Bergère A, Cyteval C, Fournier L, Malhaire C, Drape JL, Poncelet E, Bordonne C, Cauliez H, Budzik JF, Boisserie M, Willaume T, Molière S, Peyron Faure N, Caius Giurca S, Juhan V, Caramella T, Perrey A, Desmots F, Faivre-Pierre M, Abitbol M, Lotte R, Istrati D, Guenoun D, Luciani A, Zins M, Meder JF, Cotten A. Five simultaneous artificial intelligence data challenges on ultrasound, CT, and MRI. Diagn Interv Imaging 2019; 100:199-209. [DOI: 10.1016/j.diii.2019.02.001] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2019] [Accepted: 02/04/2019] [Indexed: 12/18/2022]
|
47
|
Lavoue V, Huchon C, Akladios C, Alfonsi P, Bakrin N, Ballester M, Bendifallah S, Bolze PA, Bonnet F, Bourgin C, Chabbert-Buffet N, Collinet P, Courbiere B, De la Motte Rouge T, Devouassoux-Shisheboran M, Falandry C, Ferron G, Fournier L, Gladieff L, Golfier F, Gouy S, Guyon F, Lambaudie E, Leary A, Lecuru F, Lefrere-Belda MA, Leblanc E, Lemoine A, Narducci F, Ouldamer L, Pautier P, Planchamp F, Pouget N, Ray-Coquard I, Rousset-Jablonski C, Senechal-Davin C, Touboul C, Thomassin-Naggara I, Uzan C, You B, Daraï E. Management of epithelial cancer of the ovary, fallopian tube, and primary peritoneum. Long text of the Joint French Clinical Practice Guidelines issued by FRANCOGYN, CNGOF, SFOG, and GINECO-ARCAGY, and endorsed by INCa. Part 1: Diagnostic exploration and staging, surgery, perioperative care, and pathology. J Gynecol Obstet Hum Reprod 2019; 48:369-378. [PMID: 30936027 DOI: 10.1016/j.jogoh.2019.03.017] [Citation(s) in RCA: 21] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2019] [Accepted: 03/19/2019] [Indexed: 11/27/2022]
Abstract
An MRI is recommended for an ovarian mass that is indeterminate on ultrasound. The ROMA score (combining CA125 and HE4) can also be calculated (grade A). In presumed early-stage ovarian or tubal cancers, the following procedures should be performed: an omentectomy (at a minimum, infracolic), an appendectomy, multiple peritoneal biopsies, peritoneal cytology (grade C), and pelvic and para-aortic lymphadenectomies (grade B) for all histologic types, except the expansile mucinous subtypes, for which lymphadenectomies can be omitted (grade C). Minimally invasive surgery is recommended for early-stage ovarian cancer, when there is no risk of tumor rupture (grade B). For FIGO stages III or IV ovarian, tubal, and primary peritoneal cancers, a contrast-enhanced computed tomography (CT) scan of the thorax/abdomen/pelvis is recommended (grade B), as well as laparoscopic exploration to take multiple biopsies (grade A) and a carcinomatosis score (Fagotti score at a minimum) (grade C) to assess the possibility of complete surgery (i.e., leaving no macroscopic tumor residue). Complete surgery by a midline laparotomy is recommended for advanced ovarian, tubal, or primary peritoneal cancer (grade B). For advanced cancers, para-aortic and pelvic lymphadenectomies are recommended when metastatic adenopathy is clinically or radiologically suspected (grade B). When adenopathy is not suspected and when complete peritoneal surgery is performed as the initial surgery for advanced cancer, the lymphadenectomies can be omitted because they do not modify either the medical treatment or overall survival (grade B). Primary surgery (before other treatment) is recommended whenever it appears possible to leave no tumor residue (grade B).
Collapse
Affiliation(s)
- V Lavoue
- Service de gynécologie, CHU de Rennes, Hôpital sud, 16 Bd de Bulgarie, 35000 Rennes, France; INSERM 1242, Chemistry, Oncogenesis, Stress and Signaling, Centre Eugène Marquis, Rue Bataille Flandres-Dunkerques, Rennes, France.
| | - C Huchon
- Service de Gynécologie, CHI Poissy, France
| | - C Akladios
- Service de Gynécologie, Hôpital Hautepierre, CHU Strasbourg, France
| | - P Alfonsi
- Service d'Anesthésie, Hôpital Saint Joseph, Paris, France
| | - N Bakrin
- Service de chirurgie digestive, CHU Lyon-Sud, Pierre-Bénite, Lyon, France
| | - M Ballester
- Service de gynécologie, GH Diaconesses Croix Saint Simon, Paris, France
| | - S Bendifallah
- Service de Gynécologie-Obstétrique et Médecine de la Reproduction, Hôpital Tenon, 4 rue de La Chine, APHP, Institut Universitaire de Cancérologie Sorbonne Université, UMRS-938, France
| | - P A Bolze
- Service de chirurgie gynécologique, CHU Lyon-Sud, Pierre Bénite, Lyon, France
| | - F Bonnet
- Service d'anesthésie, Hôpital Tenon, AP-HP, Paris, France
| | - C Bourgin
- Service de Chirurgie Gynécologique, Hôpital Jeanne de Flandres, CHRU, Lille, France
| | - N Chabbert-Buffet
- Service de Gynécologie-Obstétrique et Médecine de la Reproduction, Hôpital Tenon, 4 rue de La Chine, APHP, Institut Universitaire de Cancérologie Sorbonne Université, UMRS-938, France
| | - P Collinet
- Service de Chirurgie Gynécologique, Hôpital Jeanne de Flandres, CHRU, Lille, France
| | - B Courbiere
- Pôle Femmes-Parents-Enfants - Centre Clinico-Biologique d'AMP, AP-HM La Conception, 147 bd Baille, 13005 Marseille/Aix Marseille Université, CNRS, IRD, Avignon Université, IMBE UMR 7263, 13397 Marseille, France
| | | | | | - C Falandry
- Service d'oncogériatrie, Hospices civiles de Lyon, CHU Lyon-Sud, Pierre-Bénite, Lyon, France
| | - G Ferron
- Service d'oncologie chirurgicale, Institut Claudius Regaud, IUCT Oncopole, Toulouse, France
| | - L Fournier
- Service de radiologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France
| | - L Gladieff
- Service d'oncologie médicale, Institut Claudius Regaud, IUCT Oncopole, Toulouse, France
| | - F Golfier
- Service de chirurgie gynécologique, CHU Lyon-Sud, Pierre Bénite, Lyon, France
| | - S Gouy
- Service de chirurgie, Institut Gustave Roussy, Villejuif, France
| | - F Guyon
- Service de chirurgie, Institut Bergonié, Bordeaux, France
| | - E Lambaudie
- Service de chirurgie, Institut Paoli Calmette, Marseille, France
| | - A Leary
- Service d'oncologie médicale, Institut Gustave Roussy, Villejuif, France
| | - F Lecuru
- Service de chirurgie gynécologique et oncologique, Hôpital Européen Georges Pompidou, AP-HP, Paris, France
| | - M A Lefrere-Belda
- Service d'anatomo-pathologie, Hôpital Européen Georges Pompidou, AP-HP, Paris, France
| | - E Leblanc
- Service de chirurgie, Centre Oscar Lambret, Lille, France
| | - A Lemoine
- Service d'anesthésie, Hôpital Tenon, AP-HP, Paris, France
| | - F Narducci
- Service de chirurgie, Centre Oscar Lambret, Lille, France
| | - L Ouldamer
- Service de chirurgie gynécologique, CHU de Tours, France
| | - P Pautier
- Service d'oncologie médicale, Institut Gustave Roussy, Villejuif, France
| | - F Planchamp
- Service de méthodologie, Institut Bergonié, Bordeaux, France
| | - N Pouget
- Service de chirurgie, Curie (site Saint Cloud), Paris, France
| | - I Ray-Coquard
- Service d'oncologie médicale, Centre Léon Bérard, Lyon, France
| | | | | | - C Touboul
- Service de chirurgie gynécologique, CHI de Créteil, Créteil, France
| | | | - C Uzan
- Service de chirurgie et cancérologie gynécologique et mammaire, Hôpital Pitié Salpêtrière, Institut Universitaire de Cancérologie, Sorbonne Université, INSERM U938, France
| | - B You
- Service d'oncologie médicale, Institut de cancérologie des Hospices Civils de Lyon, Pierre-Bénite, Lyon, Paris, France
| | - E Daraï
- Service de Gynécologie-Obstétrique et Médecine de la Reproduction, Hôpital Tenon, 4 rue de La Chine, APHP, Institut Universitaire de Cancérologie Sorbonne Université, UMRS-938, France
| |
Collapse
|
48
|
Roblot V, Giret Y, Bou Antoun M, Morillot C, Chassin X, Cotten A, Zerbib J, Fournier L. Artificial intelligence to diagnose meniscus tears on MRI. Diagn Interv Imaging 2019; 100:243-249. [PMID: 30928472 DOI: 10.1016/j.diii.2019.02.007] [Citation(s) in RCA: 34] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2019] [Accepted: 02/27/2019] [Indexed: 10/27/2022]
Abstract
PURPOSE The purpose of this study was to build and evaluate a high-performance algorithm to detect and characterize the presence of a meniscus tear on magnetic resonance imaging examination (MRI) of the knee. MATERIAL AND METHODS An algorithm was trained on a dataset of 1123 MR images of the knee. We separated the main task into three sub-tasks: first to detect the position of both horns, second to detect the presence of a tear, and last to determine the orientation of the tear. An algorithm based on fast-region convolutional neural network (CNN) and faster-region CNN, was developed to classify the tasks. The algorithm was thus used on a test dataset composed of 700 images for external validation. The performance metric was based on area under the curve (AUC) analysis for each task and a final weighted AUC encompassing the three tasks was calculated. RESULTS The use of our algorithm yielded an AUC of 0.92 for the detection of the position of the two meniscal horns, of 0.94 for the presence of a meniscal tear and of 083 for determining the orientation of the tear, resulting in a final weighted AUC of 0.90. CONCLUSION We demonstrate that our algorithm based on fast-region CNN is able to detect meniscal tears and is a first step towards developing more end-to-end artificial intelligence-powered diagnostic tools.
Collapse
Affiliation(s)
- V Roblot
- UMR-S970, Department of Radiology, Hôpital Européen Georges-Pompidou, Assistance Publique-Hôpitaux de Paris, Université Paris-Descartes, 75015 Paris, France.
| | - Y Giret
- CentraleSupélec, Université Paris Saclay, 91190 Gif-sur-Yvette, France; Foodvisor, 75011 Paris, France
| | - M Bou Antoun
- UMR-S970, Department of Radiology, Hôpital Européen Georges-Pompidou, Assistance Publique-Hôpitaux de Paris, Université Paris-Descartes, 75015 Paris, France
| | - C Morillot
- CentraleSupélec, Université Paris Saclay, 91190 Gif-sur-Yvette, France
| | - X Chassin
- CentraleSupélec, Université Paris Saclay, 91190 Gif-sur-Yvette, France
| | - A Cotten
- Department of Musculoskeletal Radiology, Lille University Hospital, 59037 Lille, France
| | - J Zerbib
- UMR-S970, Department of Radiology, Hôpital Européen Georges-Pompidou, Assistance Publique-Hôpitaux de Paris, Université Paris-Descartes, 75015 Paris, France
| | - L Fournier
- UMR-S970, Department of Radiology, Hôpital Européen Georges-Pompidou, Assistance Publique-Hôpitaux de Paris, Université Paris-Descartes, 75015 Paris, France; Laboratoire de Recherche en Imagerie, LRI, PARCC-HEGP, UMR 970, Inserm/université Paris Descartes, Sorbonne-Paris cité, 75015 Paris, France
| |
Collapse
|
49
|
Septfons A, Goronflot T, Jaulhac B, Roussel V, De Martino S, Guerreiro S, Launay T, Fournier L, De Valk H, Figoni J, Blanchon T, Couturier E. Epidemiology of Lyme borreliosis through two surveillance systems: the national Sentinelles GP network and the national hospital discharge database, France, 2005 to 2016. Euro Surveill 2019; 24:1800134. [PMID: 30892181 PMCID: PMC6425552 DOI: 10.2807/1560-7917.es.2019.24.11.1800134] [Citation(s) in RCA: 26] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022] Open
Abstract
BACKGROUND Lyme borreliosis (LB) is the most frequent vector-borne disease in France. Since 2009, surveillance of LB is conducted by a sentinel network of general practitioners (GPs). This system, in conjunction with the national hospitalisation database was used to estimate the incidence and describe the characteristics of LB in France. AIM To describe the estimated incidence and trends in GP consultations and hospital admissions for LB in France and identify risk groups and high-incidence regions. RESULTS From 2011 to 2016, the mean yearly incidence rate of LB cases was 53 per 100,000 inhabitants (95% CI: 41-65) ranging from 41 in 2011 to 84 per 100 000 in 2016. A mean of 799 cases per year were hospitalised with LB associated diagnoses 2005-16. The hospitalisation incidence rate (HIR) ranged from 1.1 cases per 100,000 inhabitants in 2005 to 1.5 in 2011 with no statistically significant trend. We observed seasonality with a peak during the summer, important inter-regional variations and a bimodal age distribution in LB incidence and HIR with higher incidence between 5 and 9 year olds and those aged 60 years. Erythema migrans affected 633/667 (95%) of the patients at primary care level. Among hospitalised cases, the most common manifestation was neuroborreliosis 4,906/9,594 (51%). CONCLUSION Public health strategies should focus on high-incidence age groups and regions during the months with the highest incidences and should emphasise prevention measures such as regular tick checks after exposure and prompt removal to avoid infection.
Collapse
Affiliation(s)
- A Septfons
- Santé publique France, Paris, France,European Programme for Intervention Epidemiology Training (EPIET), European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden
| | - T Goronflot
- Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique IPLESP, AP-HP, Hôpital Saint Antoine, Paris, France
| | - B Jaulhac
- Early Bacterial Virulence: Lyme borreliosis Group, Université de Strasbourg, CHRU Strasbourg, Fédération de Médecine Translationnelle de Strasbourg, VBP EA 7290, Strasbourg, France,Centre National de Référence des Borrelia, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - V Roussel
- Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique IPLESP, AP-HP, Hôpital Saint Antoine, Paris, France
| | - S De Martino
- Early Bacterial Virulence: Lyme borreliosis Group, Université de Strasbourg, CHRU Strasbourg, Fédération de Médecine Translationnelle de Strasbourg, VBP EA 7290, Strasbourg, France,Centre National de Référence des Borrelia, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
| | - S Guerreiro
- Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique IPLESP, AP-HP, Hôpital Saint Antoine, Paris, France
| | - T Launay
- Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique IPLESP, AP-HP, Hôpital Saint Antoine, Paris, France
| | - L Fournier
- Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique IPLESP, AP-HP, Hôpital Saint Antoine, Paris, France
| | - H De Valk
- Santé publique France, Paris, France
| | - J Figoni
- Santé publique France, Paris, France
| | - T Blanchon
- Sorbonne Université, INSERM, Institut Pierre Louis d’Epidémiologie et de Santé Publique IPLESP, AP-HP, Hôpital Saint Antoine, Paris, France
| | | |
Collapse
|
50
|
Duron L, Balvay D, Vande Perre S, Bouchouicha A, Savatovsky J, Sadik JC, Thomassin-Naggara I, Fournier L, Lecler A. Gray-level discretization impacts reproducible MRI radiomics texture features. PLoS One 2019; 14:e0213459. [PMID: 30845221 PMCID: PMC6405136 DOI: 10.1371/journal.pone.0213459] [Citation(s) in RCA: 103] [Impact Index Per Article: 20.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2018] [Accepted: 02/21/2019] [Indexed: 12/28/2022] Open
Abstract
OBJECTIVES To assess the influence of gray-level discretization on inter- and intra-observer reproducibility of texture radiomics features on clinical MR images. MATERIALS AND METHODS We studied two independent MRI datasets of 74 lacrymal gland tumors and 30 breast lesions from two different centers. Two pairs of readers performed three two-dimensional delineations for each dataset. Texture features were extracted using two radiomics softwares (Pyradiomics and an in-house software). Reproducible features were selected using a combination of intra-class correlation coefficient (ICC) and concordance and coherence coefficient (CCC) with 0.8 and 0.9 as thresholds, respectively. We tested six absolute and eight relative gray-level discretization methods and analyzed the distribution and highest number of reproducible features obtained for each discretization. We also analyzed the number of reproducible features extracted from computer simulated delineations representative of inter-observer variability. RESULTS The gray-level discretization method had a direct impact on texture feature reproducibility, independent of observers, software or method of delineation (simulated vs. human). The absolute discretization consistently provided statistically significantly more reproducible features than the relative discretization. Varying the bin number of relative discretization led to statistically significantly more variable results than varying the bin size of absolute discretization. CONCLUSIONS When considering inter-observer reproducible results of MRI texture radiomics features, an absolute discretization should be favored to allow the extraction of the highest number of potential candidates for new imaging biomarkers. Whichever the chosen method, it should be systematically documented to allow replicability of results.
Collapse
Affiliation(s)
- Loïc Duron
- Department of Radiology, Fondation Ophtalmologique Adolphe de Rothschild, Paris, France
- Université Paris Descartes Sorbonne Paris Cité, INSERM UMR-S970, Cardiovascular Research Center—PARCC, Paris, France
| | - Daniel Balvay
- Université Paris Descartes Sorbonne Paris Cité, INSERM UMR-S970, Cardiovascular Research Center—PARCC, Paris, France
| | - Saskia Vande Perre
- Université Paris Descartes Sorbonne Paris Cité, INSERM UMR-S970, Cardiovascular Research Center—PARCC, Paris, France
| | - Afef Bouchouicha
- Université Paris Descartes Sorbonne Paris Cité, INSERM UMR-S970, Cardiovascular Research Center—PARCC, Paris, France
| | - Julien Savatovsky
- Department of Radiology, Fondation Ophtalmologique Adolphe de Rothschild, Paris, France
| | - Jean-Claude Sadik
- Department of Radiology, Fondation Ophtalmologique Adolphe de Rothschild, Paris, France
| | - Isabelle Thomassin-Naggara
- Université Paris Descartes Sorbonne Paris Cité, INSERM UMR-S970, Cardiovascular Research Center—PARCC, Paris, France
- Sorbonne Universités, UPMC Univ Paris 06, Institut Universitaire de Cancérologie, Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Tenon, Service d'Imagerie, 4 rue de la Chine, Paris, France
| | - Laure Fournier
- Université Paris Descartes Sorbonne Paris Cité, INSERM UMR-S970, Cardiovascular Research Center—PARCC, Paris, France
- Université Paris Descartes Sorbonne Paris Cité, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Radiology Department, Paris, France
| | - Augustin Lecler
- Department of Radiology, Fondation Ophtalmologique Adolphe de Rothschild, Paris, France
- Université Paris Descartes Sorbonne Paris Cité, INSERM UMR-S970, Cardiovascular Research Center—PARCC, Paris, France
| |
Collapse
|